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CHAPTER I 
 
INTRODUCTION TO SUPERPARAMAGNETIC NANOPARTICLES FOR 
INTERSTITAL APPLICATIONS 
 
Rationale 
A persistent limitation to clinical application of macromolecular therapeutic 
agents is an inability to deliver high levels of therapeutic agent throughout a specific 
tissue volume without impacting surrounding tissues. Viral vectors for gene therapy of 
both genetic defects and anticancer therapy have demonstrated substantial toxicity, and 
even death in some cases due to non-target delivery both by intravascular delivery and 
interstitial injection (1-4).  Liposomes and other micro and nano-encapsulation strategies 
that attempt to concentrate molecular therapeutics such as doxorubicin within a solid 
tissue volume have minimal penetration into the interstitium following either 
intravascular or interstitial delivery (5-9). 
Multifunctional nanoscale constructs that encompass therapeutic agents, imaging 
moieties and targeting ligands have the potential to radically change the treatment and 
morbidity profile of cancer and other significant human pathogens by synergistically 
combining enhanced targeting, reporting, and treatment of specific sites in the body.  
Application of these emerging multifunctional nanoscale constructs will be limited until 
strategies for comprehensive solid tissue access are developed.   
Solid tissue transport is governed by fluid forces, such as diffusion and 
convection, geometric factors, such as steric hindrance, and by molecular interactions, 
including nonspecific adsorption.  Fluid transport in the interstitial space has been 
 
characterized both for molecular, and nanoscale therapeutics.  Molecular interactions 
between therapeutic constructs and biological surfaces have been addressed through the 
development of biocompatible coatings (e.g. polyethylene glycol).  Strategies for 
overcoming geometric barriers to macromolecular therapeutic delivery are only now 
emerging (10, 11).  Within this dissertation, strategies for overcoming these steric 
barriers will be addressed.  
The most effective route of administration for a therapeutic agent is determined 
by the physiology of target tissue(s) and the characteristics of the therapeutic agent.  
Some administration routes provide higher drug concentrations in specific physiological 
compartments (e.g. intramuscular/intratissue injection, nasal/mucosal, ocular) and other 
routes are characteristic of rapid access to multiple tissues (e.g. oral/gastrointestinal, 
intravascular injection).  The administration of therapeutic agents that are larger than 
small molecules must consider the exceptionally limited mobility of large molecules 
within solid tissues.  Pharmacokinetic distributions are significantly modulated by the 
physical, chemical and biological characteristics of the therapeutic agent.  The 
biodistribution for large therapeutic agents is generally poor, even within sites that allow 
administration by multiple interstitial injections. 
The rate of therapeutic agent transport is controlled by the relative strengths of 
mechanisms that enable motion and corresponding resistances modulated by 
proportionality factors controlled by physical characteristics.  Mobility can be increased 
by appropriate change in any of these three transport aspects.  The work described here 
leverages the improvement in biotransport that may be achieved through addition of a 
mechanism to enable motion and an approach to reduce the local resistance to motion.  
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Specifically, the simultaneous application of a magnetic force on the therapeutic 
construct and the use of proteolysis to reduce tissue resistance to improve the 
biodistribution of nanoscale agents are explored in this study. 
Early efforts to develop magnetic nanoparticles for therapeutic applications 
demonstrated the potential to apply a substantial force to superparamagnetic structures in 
the vasculature (12, 13).  Studies have demonstrated that lytic enzymes such as 
collagenase or hyluronidase can have a substantial impact on the passive mobility of 
macromolecules in the interstitial space (10, 11). Based on this evidence, I propose to 
enhance the distribution of macromolecular therapies and nanostructures such as some 
chemotherapy agents, radiotherapy seeds, or gene therapy vectors within a tissue volume 
by utilizing a proteolytic superparamagnetic nanoparticle carrier.  
 
Specific Aims 
I propose to explore magnetic nanoparticle carriers for interstitial dispersion over the 
course of three specifics aims:  
 
Aim I – Characterize interstitial transport of SPM NPs in in vitro tissue models and 
murine subjects. 
I propose to provide an integrated, calculation-based characterization of 
interstitial SPM NP mobility.  I will computationally estimate the forces that influence 
the motion of SPM NPs in tumor interstitium. Computational findings will be tested in in 
vitro tissue models.  Based on the calculation and in vitro experimental findings, I will 
image interstitial transport of SPM NPs in a murine solid tumor.  SPM NP mobility will 
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be modulated by an external magnetic field and will be quantitatively imaged using two-
dimensional x-ray imaging. 
 
Aim II – Investigate NP-linked enzyme degradation of steric barriers to interstitial NP 
mobility. 
I propose to develop a mobile construct capable of local modification of the 
interstitial space.  To enhance NP mobility by interstitial remodeling, I will develop a 
collagenase-SPM NP construct. I will quantify NP-collagenase proteolytic activity and 
NP-collagenase construct stability in an in vitro system.  Based on the in vitro evidence, I 
will quantitatively assess NP-collagenase particle mobility in ex vivo tumor sections by 
high-resolution, semiquantitative CT imaging and quantitative fluorescent imaging. 
 
Aim III – Develop a multivalent enzyme-nanoparticle synthesis strategy. 
I propose to demonstrate a multifunctional nanoparticle that has efficacy against 
two or more classes of biological substrates, including carbohydrates (α-glucosidase) and 
proteins (collagenase).  To facilitate future multifunctional nanoparticle development, I 
will examine the cross reactivity of the target enzymes in each enzyme activity assay 
system.  I will leverage synthetic strategies developed in Aim II to provide a 
straightforward, inexpensive synthetic strategy. 
 
Significance 
This body of work makes several contributions to the development of 
macromolecular and nanoparticle-based therapeutic agents for interstitial applications.  
The in vitro interstitial model system detailed in Manuscripts 1 and 2 is a simple and 
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flexible assay system that provides quantitative data suitable for mathematical description 
of nanoparticle interactions with the extracellular matrix.  Creation of proteolytic 
enzyme-nanoparticle conjugates will allow study of individual enzymatic elements 
during invasive cellular processes such as metastasis or neuronal development 
(Manuscripts 2 and 3).  Clinical development of proteolytic enzyme-nanoparticle 
conjugates will allow minimally invasive and enhanced dispersion of otherwise immobile 
macromolecular and nanoscale therapies in solid tissue.  Demonstration of multivalent 
enzyme-nanoparticle conjugates provides a foundation for generalized multifunctional 
biomolecule-nanoparticles that incorporate enzymatic activity, receptors or ligands, 
imaging agents, and radio- or thermotherapeutic elements in a single nanoparticle 
structure (Manuscript 3). 
 
Background 
Despite the prominence of cancer in terms of both academic study and financial 
expenditure, more than 1.2 million people in the United States were diagnosed with this 
disease in 1999.  Over 500,000 people died of cancer in 1999 (14).  The continued 
prevalence of cancer diagnosis and death necessitate new efforts to develop novel 
therapies for treatment. 
 
Treatment Strategies Are Limited by Tumor Physiology 
 Tumor physiology and structure limit therapeutic approaches.  Diffusion-driven 
mobility is insufficient to disperse some therapeutic agents (TAs) throughout a modest 
tumor volume (15, 16).  A high interstitial pressure gradient generated by leaky 
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vasculature drives molecular TAs out of the tumor volume via convection.  Therapeutic 
agents larger than ten nanometers have high retention rates within tumor tissue due to 
their negligible intrinsic mobility (17).  Vascular delivery of TAs to tumor is complicated 
by nonspecific delivery and retention in cardiovascular filtration systems (18).  The 
anatomy and physiology of the tumor cause irregular deposition of therapeutic agents that 
leads to incomplete treatment of the tumor volume (19). Macromolecular therapies (e.g. 
antibodies or NPs) face additional steric restrictions to interstitial motion from the 
interstitial collagen network (20).  Current intravascular and interstitial delivery and 
dispersion strategies for NP-based therapeutic strategies are limited in their application 
due to a lack of precise intravascular delivery and effective, long-term interstitial 
dispersion. 
 
Better Biodistribution and Enhanced Specific Delivery Towards Improved Treatment 
Enhanced distribution of TAs within the tumor can be achieved by increasing the 
retention time of the TA within the tumor and by increasing therapy mobility within the 
tumor.  Enzyme-linked SPM NPs minimize undirected passive motion while maximizing 
targeted motion with the tumor volume.  Enzymatic degradation of the interstitial 
network allows use of otherwise inadequately mobile SPM NPs as therapeutic agents. 
 
Prior Evidence of Magnetic Targeting of TAs 
Qualitative evidence of enhanced retention and deposition of intravascularly 
delivered SPM NP therapy carriers in specific tumors has been reported. Retention of 
magnetic particles on the order of 1 μm diameter in specific regions of an animal 
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following intravascular administration has been documented by Gruttner et al (21).  
Gruttner et al.’s work, however, found only a 25-30% increase in retention of the 
magnetic particles in the presence of a 0.4 T magnet field.  The remainder of the particles 
was found in the liver of the animals.  This level of liver delivery is indicative of first-
pass capture by filtering processes and highlights the need for a long-circulating magnetic 
particle.  Gruttner et al. dismisses NPs less than 100 nm in diameter for use in vivo due to 
their poor magnetic mobility in contradiction with other existing work (22, 23).  
Minimizing NP size is desirable due to a corresponding reduction in NP elimination by 
filtration (18). 
Publications by other scientists affiliated with FeRx Incorporated (San Diego, 
CA) suggest that ferromagnetic particles on the order of 1 μm may be suitable for site-
specific intravascular or intravesical delivery.  Rudge et al. found that particle retention 
could exceed 90% for a 1 μm iron particle (FeRx MTCs) in an in vitro model vascular 
system consisting of a 35% glycerol solution flowing at 0.2 cm/s through a hollow fiber 
cartridge in a 0.01 T field (24).  However, no negative control data was presented, 
leaving significant concerns regarding the passive trapping of particles by the hollow 
fibers in the cartridge. During in vivo studies, FeRx scientists demonstrated the local 
intravascular delivery of doxorubicin on a magnetically targeted carrier particle (MTC) to 
the liver under the exposure of an external magnetic field (25).  The level of retention in 
the liver tissue was not documented quantitatively nor was the retention rate of particles 
not under the influence of an external magnetic field measured.  Intravesical injection of 
doxorubicin loaded MTCs into porcine bladder and subsequent magnetic guidance into 
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the bladder wall demonstrated enhanced site-specific delivery of doxorubicin over free 
doxorubicin treatment (26). 
Goodwin et al. documented success specifically targeting FeRx particles to lung 
or liver lobes following injection in the upstream blood supply of the target organ after a 
period of 60 minutes (27).  The remainder of the MTCs was found distributed in the 
bladder, salivary glands and thyroid in both targeted organ studies.  Early literature 
reports of interstitial application of magnetic NPs were restricted to incidental findings in 
intravascular delivery studies (28).  More recently, FeRx Corporation has investigated 
delivery of MTCs to the bladder wall interstitial space from the bladder lumen (26).  
Additionally, Hooligan et al. reported limited mobility of SPM NPs in an in vitro model 
of the vitreous of the eye (29).  Interest in the application of SPM NPs to biological 
systems is evident in the annual biological/medical applications special issue of the 
Journal of Magnetism and Magnetic Materials. 
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A 
 
B 
Figure 1. Illustration of desired goal of enhancing SPM NP with an external magnetic 
field.  NPs (green) injected into a tumor without an external force (panel A) remain in the 
needle track or in the initial injection volume.  SPM NPs injected into a tumor in the 
presence of an external magnetic field source (gray box) spread throughout the tumor 
volume due to their greatly enhanced mobility (panel B). 
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NP Toxicity 
The complex nature of SPM NP-TA constructs requires examination of the 
chemical nature of the NP for toxicity as well as the possible immunogenic structures 
contained on the surface of the NP.  Hafeli et al. examined the toxicity of iron oxide and 
iron NPs and determined that the coating of the NP generally is a strong indicator of the 
toxicity profile of the NPs in vivo (30).  Unfortunately, a large fraction of Hafeli et al.’s 
data was not statistically significant, limiting the interpretation of their work. Long term, 
the degradation of the particles may result in liberation of the core materials of the 
particle.  Liberation of iron from particles is unlikely to be a significant concern, as the 
level of free iron known to be toxic to humans is on the order of 260 mg per kilogram, 
well above any potential levels found in any iron-particle therapeutic strategy (31). Iron-
containing SPM NPs have been safely utilized for contrast enhanced MRI imaging in 
human subjects (32). 
 
Quantitative imaging of interstitial transport of SPM NPs 
 The iron content of SPM NPs allows quantitative spatial and temporal x-ray and 
CT imaging of NP localization, concentration, and mobility within a tumor volume or 
tissue sample (33).  High-resolution electron microscopy imaging of the particle 
interaction with interstitial structures is also possible due to the iron content of the SPM 
NPs (34, 35).  The wide variety of commercially available surface treatments for NP also 
allows fluorescence quantification of NP mobility and position (micromod, Spherotech, 
Pierce, etc.).  SPM NP transport may be compared with previous in vivo studies of 
macromolecular therapy constructs by quantitative imaging (36-40).   
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Prior evidence of NP motion in interstitium 
Jain and Yuan, among others, have studied interstitial microstructures extensively 
through the use of a variety of in vitro and in vivo techniques (41-46). While the tumor 
vasculature has been found to allow passive extravasation of NPs as large as 700 
nanometers, in vitro experiments have shown the interstitial space to sharply limit passive 
motion of macromolecules larger than 10-15 nanometers in diameter (46, 47).  
Computational work by Yuan et al. has also suggested a diameter limit of approximately 
10 nanometers for unimpeded diffusion or convection-driven motion of macromolecules 
in the interstitium (17). 
NP motion through the interstitial space is retarded by the presence of the network 
of extracellular proteins and carbohydrates.  The network of proteins in the interstitium 
forms channels and pores, creating a barrier to NP motion through the tissue.  Netti et al. 
have identified the collagen fiber network as the most significant barrier to passive NP 
motion in the interstitium (10).  The collagen fiber network has been estimated to have 
gaps ranging from 20-42 nanometers in “dense” tumors to 75-130 nanometers in “soft” 
tumors (48). These narrow gaps in the collagen network form a physical barrier to 
passive NP motion.  Hyaluronic acid has been implicated as a barrier biomolecule in the 
center of a tumor (48).   
 
ECM protein network resistance 
Due, in part, to the historic difficulties in precision manufacturing of useful 
nanoscale therapy carriers, the body of evidence available regarding quantitative 
measurement of interstitial NP transport is limited.  The paucity of published reports is an 
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opportunity to lay the groundwork for interstitial NP applications through computational 
models and quantitative imaging studies of interstitial NP dynamics. 
 Some evidence of nanoscale structural behavior can presumably be extrapolated 
from studies of antibody mobility in the interstitium (20).  Pluen et al. identified the 
collagen content, rather than the glycosaminoglycan concentration, of a tumor as the 
primary source of decreased antibody mobility.  Treatment of the tumor with collagenase 
for 24 hours was shown to increase antibody diffusion by 100% (10).   
Invasive bacteria and viruses, ranging in size from 100 nm to 2000 nm, are 
nanoscale structures with enhanced interstitial mobility. The microorganisms utilize 
surface bound and secreted enzymes to increase their access to distant tissues.  Invasion 
into the interstitial space relies on proteases such as collagenase as well as other 
nonspecific proteolytic enzymes (49-51).  Nonspecific degradation of the extracellular 
and cellular space serves to cause inflammation and fluid retention, easing the passive 
convective or active transport of the organism to distant sites (52-54). 
 
Calculation of interstitial forces acting on SPM NPs 
 Physical properties of the SPM NPs and known, or estimated, characteristics of 
the tumor obtained from literature may be used to estimate the net force acting on the 
SPM NPs.  The net force acting on the SPM NPs is a function of the drag force, buoyant 
force, and magnetic force, in addition to contributions from diffusion and convection.  
Based on the work of Zbrowski, Hooligan et al. developed a mathematical model that 
describes the mobility of nanoparticles in the interstitial space (29, 55).  The model 
developed by Hooligan provides a predictive measure for estimating the fluid-phase 
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interstitial velocity of SPM NPs based on magnetic and fluid parameters.  These 
estimations of mobility may be utilized to narrow the investigation of candidate SPM 
NPs for interstitial applications. 
 
In vitro tissue models, previous findings 
Diffusive mobility is sufficient to saturate a 200 micron diameter tumor in 
approximately six hours with a small chemical agent (15, 16).  While molecular therapies 
may have sufficient diffusion or convection driven mobility within the tumor volume, the 
motion of those agents is driven by concentration/pressure gradients not applicable to 
therapeutic goals.  Agents of sizes larger than five nanometers (e.g. viruses, nonviral gene 
therapy constructs, NP carriers) remain largely within the initial injection volume as is 
shown in Figure 2.  A variety of mechanisms presumably contribute to this low mobility 
behavior, including nonspecific adsorption of the virus to the surrounding biological 
environment and limited initial tissue penetration by the injection volume (3, 19, 56). 
13 
  
Figure 2.  Anti-tumor necrosis factor (TNF) staining of cells by viral gene therapy vector 
(brown) along the needle injection track.  Tissue is counterstained (blue) (Hallahan, 
unpublished). 
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The role of proteolytic activity in biological processes 
Collagenase, and other related MMP have been an exceptionally active area of 
research due to their involvement in tissue rearrangement during development and cancer 
metastasis (57-59).  MMP and MMP inhibitor involvement in wound healing, both as a 
therapeutic agents and as native processes, have been well characterized (60-62).  
Proteases that degrade the structural components of the extracellular matrix are also 
found on invasive microorganisms in the genera Bacteroides, Clostridium, and 
Peptostreptococcus (54), enabling alteration of the local structural environment to allow 
active mobility to distant sites in the host organism. 
 
Strategies to link functional enzymes to the NP surface 
 Sophisticated strategies for linking biomolecules to NPs based on methods of 
modern immunology are available.  The synthetic approach developed by Duncan et al. 
incorporates simple covalent modification reagents N-succinimidyl-S-
acetylthiopropionate (SATP) and sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-
1-carboxylate (sulfo-SMCC) (63).  SATP is a well-characterized reagent that modifies 
primary amines to sulfhydryl groups.  Sulfo-SMCC is a heterobifunctional crosslinker 
that converts primary amines to maleimide reactive groups.  Together, these two reactive 
chemicals form a covalent thioether linkage between structures suitable for NP-
therapeutic agent conjugation. 
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Quantification of NP-bound enzyme activity 
Due to the SPM nature of the NPs in this proposal, magnetic purification of the 
NP-enzyme construct is possible.  Quantification strategies for total enzyme binding and 
enzymatic function have both been developed into commercially available kits (Pierce, 
Invitrogen).  Total protein activity may be assessed by simple spectroscopic detection of 
fluorogenic amino acids (i.e. tryptophan), or through traditional histological staining 
techniques.  Quantification of NP-bound enzyme activity can be assessed through 
zymography, dye-quenched fluorogenic substrates, or colorimetric substrates (64).  The 
tools required for quantitative assessment of enzyme activity, even for proteins 
conjugated to the NP surface, are available. 
 
Summary 
Specific Aim I builds upon magnetic targeting evidence and low iron-based 
nanoparticle toxicity previous reported in the literature by Goodwin and others to develop 
an in vitro and calculational means to characterize and quantify NP mobility in the 
interstitial space.  A proteolytic enzyme-nanoparticle construct is proposed in Specific 
Aim II based on previous biomolecule conjugation strategies to overcome the specific 
protein barriers, such as collagen I fibers, which form a steric barrier to NP interstitial 
motion.  Finally, the collagenase-nanoparticle enzyme from Specific Aim II is extended 
to create multifunctional nanoparticles that are modeled after existing lytic sets of 
proteins in invasive cells in Specific Aim III. 
16 
References 
 
1. Lozier, J.N., et al., Toxicity of a first-generation adenoviral vector in rhesus 
macaques. Hum Gene Ther, 2002. 13(1): p. 113-24. 
2. Marshall, E., Gene therapy death prompts review of adenovirus vector. Science, 
1999. 286(5448): p. 2244-5. 
3. Zhang, R., F.H. Straus, and L.J. DeGroot, Effective genetic therapy of established 
medullary thyroid carcinomas with murine interleukin-2: dissemination and 
cytotoxicity studies in a rat tumor model. Endocrinology, 1999. 140(5): p. 2152-8. 
4. Paielli, D.L., et al., Evaluation of the biodistribution, persistence, toxicity, and 
potential of germ-line transmission of a replication-competent human adenovirus 
following intraprostatic administration in the mouse. Mol Ther, 2000. 1(3): p. 
263-74. 
5. Yuan, F., et al., Microvascular permeability and interstitial penetration of 
sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res, 
1994. 54(13): p. 3352-6. 
6. Zhou, R., R. Mazurchuk, and R.M. Straubinger, Antivasculature effects of 
doxorubicin-containing liposomes in an intracranial rat brain tumor model. 
Cancer Res, 2002. 62(9): p. 2561-6. 
7. Trubetskoy, V.S., et al., Massage-induced release of subcutaneously injected 
liposome-encapsulated drugs to the blood. J Control Release, 1998. 50(1-3): p. 
13-9. 
8. Kostarelos, K., et al., Binding and interstitial penetration of liposomes within 
avascular tumor spheroids. Int J Cancer, 2004. 112(4): p. 713-21. 
9. Kostarelos, K., et al., Engineering lipid vesicles of enhanced intratumoral 
transport capabilities: correlating liposome characteristics with penetration into 
human prostate tumor spheroids. J Liposome Res, 2005. 15(1-2): p. 15-27. 
10. Netti, P.A., et al., Role of extracellular matrix assembly in interstitial transport in 
solid tumors. Cancer Research, 2000. 60(9): p. 2497-503. 
11. Alexandrakis, G., et al., Two-photon fluorescence correlation microscopy reveals 
the two-phase nature of transport in tumors. Nat Med, 2004. 10(2): p. 203-7. 
12. Pulfer, S.K. and J.M. Gallo, Enhanced brain tumor selectivity of cationic 
magnetic polysaccharide microspheres. Journal of Drug Targeting, 1998. 6(3): p. 
215-27. 
17 
13. Goodwin, S.C., et al., Single-dose toxicity study of hepatic intra-arterial infusion 
of doxorubicin coupled to a novel magnetically targeted drug carrier. 
Toxicological Sciences, 2001. 60(1): p. 177-83. 
14. Group, U.S.C.S.W., United States Cancer Statistics: 1999 Incidence. 2002, 
Department of Health and Human Services,Centers for Disease Control and 
Prevention and National Cancer Institute: Atlanta, GA. 
 
15. Raghavarao, K.S., M. Dueser, and P. Todd, Multistage magnetic and 
electrophoretic extraction of cells, particles and macromolecules. Advances in 
Biochemical Engineering-Biotechnology, 2000. 68: p. 139-90. 
16. Au, J.L., et al., Determinants of drug delivery and transport to solid tumors. 
Journal of Controlled Release, 2001. 74(1-3): p. 31-46. 
17. Yuan, F., A. Krol, and S. Tong, Available space and extracellular transport of 
macromolecules: effects of pore size and connectedness. Annals of Biomedical 
Engineering, 2001. 29(12): p. 1150-8. 
18. Sugibayashi, K.a.M., Y., Biomedical Applications of Magnetic Drug Carriers in 
Cancer Chemotherapy, in Polymeric Nanospheres and Microparticles. 1986, 
CRC Press: Boca Raton, FL. p. 95-133. 
19. Wang, Y., et al., Systemic dissemination of viral vectors during intratumoral 
injection. Mol Cancer Ther, 2003. 2(11): p. 1233-42. 
20. Pluen, A., et al., Role of tumor-host interactions in interstitial diffusion of 
macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A, 
2001. 98(8): p. 4628-33. 
21. Gruttner, C., Teller, J, Schutt, W, Westphal, F., Chumichen, C., Paulke, B.R., 
Prepartation and Characterization of Magnetic Nanospheres For In Vivo 
Application, in Scientific and Clinical Applications of Magnetic Carriers, U. 
Hafeli, Schutt, W., Teller, J., Zborowski, M., Editor. 1997, Plenum Press: New 
York, New York. p. 53-67. 
22. Miltenyi, S., et al., High gradient magnetic cell separation with MACS. 
Cytometry, 1990. 11(2): p. 231-8. 
23. Prestvik, W.S., Berge, A., Mork, P.C., Stenstad, P.M., Ugelstad, J., Preparation 
and Application of Monosize Magnetic Particles in Selective Cell Separation, in 
Scientific and Clinical Applications of Magnetic Carriers, U. Hafeli, Schutt, W., 
Teller, J., Zborowski, M., Editor. 1997, Plenum Press: New York, New York. p. 
11-33. 
24. Rudge, S.R., et al., Preparation, characterization, and performance of magnetic 
iron-carbon composite microparticles for chemotherapy. Biomaterials, 2000. 
21(14): p. 1411-20. 
18 
25. Rudge, S., et al., Adsorption and desorption of chemotherapeutic drugs from a 
magnetically targeted carrier (MTC). Journal of Controlled Release, 2001. 74(1-
3): p. 335-40. 
26. Leakakos, T., et al., Intravesical administration of doxorubicin to swine bladder 
using magnetically targeted carriers. Cancer Chemother Pharmacol, 2003. 51(6): 
p. 445-50. 
27. Goodwin, S.C., et al., Targeting and retention of magnetic targeted carriers 
(MTCs) enhancing intra-arterial chemotherapy. Journal of Magnetism and 
Magnetic Materials, 1999. 194: p. 132-139. 
28. Lubbe, A.S., et al., Clinical experiences with magnetic drug targeting: a phase I 
study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer 
Research, 1996. 56(20): p. 4686-93. 
29. Holligan, D.L., G.T. Gillies, and J.P. Dailey, Magnetic guidance of ferrofluidic 
nanoparticles in an in vitro model of intraocular retinal repair. Nanotechnology, 
2003. 14(6): p. 661-666. 
30. Hafeli, U. and G.J. Pauer, In vitro and in vio toxicity of magnetic microspheres. 
Journal of Magnetism and Magnetic Materials, 1999. 194(01): p. 76-82. 
31. ACS Material Safety Data Sheet: "Iron (III) Chloride Hexahydrate - Ferric 
Chloride". 1998. 
32. Torchia, M.G., et al., Interstitial MR lymphangiography for the detection of 
sentinel lymph nodes. Journal of Surgical Oncology, 2001. 78(3): p. 151-6; 
discussion 157. 
33. Gneveckow, U., et al., Description and characterization of the novel 
hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid 
hyperthermia. Med Phys, 2004. 31(6): p. 1444-51. 
34. Jendelova, P., et al., Magnetic resonance tracking of transplanted bone marrow 
and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and 
spinal cord. J Neurosci Res, 2004. 76(2): p. 232-43. 
35. Jendelova, P., et al., Imaging the fate of implanted bone marrow stromal cells 
labeled with superparamagnetic nanoparticles. Magn Reson Med, 2003. 50(4): p. 
767-76. 
36. Peira, E., et al., In vitro and in vivo study of solid lipid nanoparticles loaded with 
superparamagnetic iron oxide. Journal of Drug Targeting, 2003. 11(1): p. 19-24. 
37. Brown, E., et al., Dynamic imaging of collagen and its modulation in tumors in 
vivo using second-harmonic generation. Nat Med, 2003. 9(6): p. 796-800. 
19 
38. Davies Cde, L., et al., Comparison of IgG diffusion and extracellular matrix 
composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids 
reveals the role of host stromal cells. Br J Cancer, 2002. 86(10): p. 1639-44. 
39. Illum, L., et al., Development of systems for targeting the regional lymph nodes 
for diagnostic imaging: in vivo behaviour of colloidal PEG-coated magnetite 
nanospheres in the rat following interstitial administration. Pharmaceutical 
Research, 2001. 18(5): p. 640-5. 
40. Weissig, V., J.W. Babich, and V.P. Torchilin, Long-circulating gadolinium-
loaded liposomes: potential use for magnetic resonance imaging of the blood 
pool. Colloids and Surfaces B: Biointerfaces, 2000. 18: p. 293-299. 
41. Leunig, M., et al., Angiogenesis, microvascular architecture, 
microhemodynamics, and interstitial fluid pressure during early growth of human 
adenocarcinoma LS174T in SCID mice. Cancer Research, 1992. 52(23): p. 6553-
60. 
42. Yuan, F., et al., Microvascular permeability of albumin, vascular surface area, 
and vascular volume measured in human adenocarcinoma LS174T using dorsal 
chamber in SCID mice. Microvascular Research, 1993. 45(3): p. 269-89. 
43. Yuan, F., et al., Vascular permeability and microcirculation of gliomas and 
mammary carcinomas transplanted in rat and mouse cranial windows. Cancer 
Research, 1994. 54(17): p. 4564-8. 
44. Lichtenbeld, H.C., et al., Perfusion of single tumor microvessels: application to 
vascular permeability measurement. Microcirculation, 1996. 3(4): p. 349-57. 
45. Monsky, W.L., et al., Regulation of transport pathways in tumor vessels: role of 
tumor type and microenvironment. Proceedings of the National Academy of 
Sciences of the United States of America, 1998. 95(8): p. 4607-12. 
46. Monsky, W.L., et al., Augmentation of transvascular transport of macromolecules 
and nanoparticles in tumors using vascular endothelial growth factor. Cancer 
Research, 1999. 59(16): p. 4129-35. 
47. McGuire, S. and F. Yuan, Quantitative analysis of intratumoral infusion of color 
molecules. American Journal of Physiology - Heart & Circulatory Physiology, 
2001. 281(2): p. H715-21. 
48. Pluen, A., et al., Role of tumor-host interactions in interstitial diffusion of 
macromolecules: cranial vs. subcutaneous tumors. Proceedings of the National 
Academy of Sciences of the United States of America, 2001. 98(8): p. 4628-33. 
49. Tamura, F., et al., Proapoptotic effect of proteolytic activation of matrix 
metalloproteinases by Streptococcus pyogenes thiol proteinase (Streptococcus 
pyrogenic exotoxin B). Infect Immun, 2004. 72(8): p. 4836-47. 
20 
50. Avidano, M.A., et al., Analysis of protease activity in human otitis media. 
Otolaryngol Head Neck Surg, 1998. 119(4): p. 346-51. 
51. Smola-Hess, S., et al., Expression of membrane type 1 matrix metalloproteinase 
in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and 
HPV8 E7 gene products. J Gen Virol, 2005. 86(Pt 5): p. 1291-6. 
52. Buczko, W., et al., Biological effects of degradation products of collagen by 
bacterial collagenase. British Journal of Pharmacology. Aug;69(4):551-4, 1980. 
53. Sela, M.N., et al., Enzymatic degradation of collagen-guided tissue regeneration 
membranes by periodontal bacteria. Clinical Oral Implants Research. 
Jun;14(3):263-8, 2003. 
54. Steffen, E.K. and D.J. Hentges, Hydrolytic enzymes of anaerobic bacteria isolated 
from human infections. Journal of Clinical Microbiology. Aug;14(2):153-6, 1981. 
55. Zborowski, M., et al., Analytical magnetapheresis of ferritin-labeled lymphocytes. 
Anal Chem, 1995. 67(20): p. 3702-12. 
56. Bledsoe, A.W., G.Y. Gillespie, and C.D. Morrow, Targeted foreign gene 
expression in spinal cord neurons using poliovirus replicons. J Neurovirol, 2000. 
6(2): p. 95-105. 
57. Hendrix, M.J., et al., Remodeling of the microenvironment by aggressive 
melanoma tumor cells. Ann N Y Acad Sci, 2003. 995: p. 151-61. 
58. Vaillant, C., et al., MMP-9 deficiency affects axonal outgrowth, migration, and 
apoptosis in the developing cerebellum. Mol Cell Neurosci, 2003. 24(2): p. 395-
408. 
59. Friedl, P. and K. Wolf, Proteolytic and non-proteolytic migration of tumour cells 
and leucocytes, in Proteases and the Regulation of Biological Processes. 2003. p. 
277-285. 
60. Aldemir, M., et al., Effectiveness of collagenase in the treatment of 
sacrococcygeal pilonidal sinus disease. Surgery Today.;33(2):106-9, 2003. 
61. Mekkes, J.R., et al., In vitro tissue-digesting properties of krill enzymes compared 
with fibrinolysin/DNAse, papain and placebo. Int J Biochem Cell Biol, 1997. 
29(4): p. 703-6. 
62. Moorhead, L.C. and N. Radtke, Enzyme-assisted vitrectomy with bacterial 
collagenase. Pilot human studies. Retina. Spring-Summer;5(2):98-100, 1985. 
63. Duncan, R.J., P.D. Weston, and R. Wrigglesworth, A new reagent which may be 
used to introduce sulfhydryl groups into proteins, and its use in the preparation of 
conjugates for immunoassay. Anal Biochem, 1983. 132(1): p. 68-73. 
21 
64. McIntyre, J.O., et al., Development of a novel fluorogenic proteolytic beacon for 
in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 
activity. Biochem J, 2004. 377(Pt 3): p. 617-28. 
 
 
22 
CHAPTER II 
 
 
 
MANUSCRIPT 1: CHARACTERIZATION OF SUPERPARAMAGNETIC  
 
NANOPARTICLE INTERACTIONS WITH EXTRACELLULAR MATRIX IN AN IN  
 
VITRO SYSTEM 
 
 
 
Sam J Kuhn1 
 
Dennis E Hallahan1,2,3 
 
Todd D Giorgio1
 
 
 
1Department of Biomedical Engineering 
 
Vanderbilt University 
 
Nashville, TN 
 
 
2Department of Radiation Oncology 
 
Vanderbilt University School of Medicine 
 
Nashville, TN 
 
 
 
3Department of Cancer Biology 
 
Vanderbilt-Ingram Cancer Center 
 
Vanderbilt University School of Medicine 
 
Nashville, TN 
 
 
 
(This manuscript is in press in Annals of Biomedical Engineering) 
23 
Abstract 
 
Controlled dispersion of therapeutic agents within liquid and gel filled cavities 
represents a barrier to treatment of some cancers and other pathological states.  Interstitial 
delivery is compromised by the poor mobility of macromolecules and larger nanoscale 
structures. We developed an in vitro system to quantify the suitability of 
superparamagnetic nanoparticles (SPM NPs) as a site-specific therapeutic vehicle for 
delivery through fluid and gel based systems. SPM NP motion was induced by an 
external magnetic field.  NP migration was modulated by NP concentration and surface 
coating.  135 nm radius PEGylated NPs moved through the extracellular matrix with an 
average velocity of 1.5 mm hr-1, suitable for some clinical applications. Increasing the 
SPM NP radius to 400 nm while maintaining the same per NP magnetic susceptibility 
resulted in a greater than 1000 fold reduction in magnetic mobility, to less than 0.01 mm 
hr-1.  The critical influence of NP size on gel permeation was also observed in silica 
coated 135 nm SPM NPs that aggregated under the experimental conditions. Aggregation 
played a critical role in determining the behavior of the nanoparticles. SPM NPs allow 
significant free-solution mobility to specific sites within a cavity and generate sufficient 
force to penetrate common in vivo gels.  
 
Introduction 
Superparamagnetic nanoparticle (SPM NP) therapeutic carriers hold the promise 
of site-specific delivery in a cavity, even in the presence of common biological barriers. 
Treatment of specific lesions or target tissues in a biological cavity has historically been 
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achieved by cavity lavage, or direct injection of a therapeutic agent at the target location.  
Lavage results in nonspecific delivery of the therapeutic agent to all surfaces within a 
cavity (1).  Therapeutic agent penetration at the target site is limited by surface coatings 
such as biogels or membranes that block free agent mobility by adhesion or steric 
hindrance (2, 3).  Direct injection is limited in its utility to sites that are accessible by a 
needle and to strategies that utilize small therapeutic molecules.   
Biodistribution of therapeutic agents is controlled by the physics of mass 
transport. Diffusion is controlled by the molecular diameter, concentration, and the 
physical properties of the surrounding medium.  Small molecules diffuse within a gel or 
fluid volume over the course of several hours (4).  For therapies larger than small 
molecules, such as viral vectors, diffusion is negligible on the time scale appropriate for 
therapeutic action (5).   
Despite velocities on the order of 5 cm s-1 in some cavities, convective therapeutic 
agent delivery has limited utility due to nonspecific delivery of therapeutic agents (6, 7).  
Convective delivery is further limited by the significant barrier of mucus and other 
proteinaceous gels characteristic of many cavities.  These gels resist convective mobility 
and substantially reduce the diffusive mobility of introduced agents (3).  Nanoparticle 
therapeutic carrier mobility can be additionally hindered by molecular interactions at the 
surface of target tissue, such as charge-charge attraction or nonspecific adhesion.  
Direct injection into target tissue delivers therapy only to the needle track and to 
the immediately surrounding tumor tissue (4, 8, 9).  This restricted biodistribution limits 
the therapeutic effect of injected agents.  Interstitial convective mass transport depends 
on the presence of a fluid velocity gradient.  In tumor tissue, the pressure difference and 
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corresponding fluid velocity gradient points radially outward from the necrotic core, 
discharging the therapy from the tumor.  Convective fluid motion is capable of 
transporting macromolecules (e.g. antibodies) within tumor tissue only over a 
submillimeter distance during a therapeutic time window (10).   
Interstitial NP motion is retarded by the presence of the network of extracellular 
proteins and carbohydrates.   Netti et al. have identified the collagen fiber network as the 
most significant barrier to passive NP motion in the interstitium (11).  The collagen fiber 
network in the ECM has been estimated to have gaps ranging from 20-42 nm in “dense” 
tumors to 75-130 nm in “soft” tumors (12). These gaps in the collagen network form a 
physical barrier to passive NP motion.  Hyaluronic acid has been implicated as a barrier 
protein in the center of the tumors (12).  In addition to the physical barriers formed by 
protein and carbohydrate networks within the tumor interstitium, NP interactions with 
surrounding tissue, soluble proteins, carbohydrates, and other NPs also reduce interstitial 
transit of NPs.  These interactions may lead to adhesion of the NPs to fixed structures or 
may result in the formation of NP agglomerates consisting of NPs and the biomolecules 
that strongly interact with them.   
Jain and Yuan, among others, have studied interstitial microstructure extensively 
through the use of a variety of in vitro and in vivo techniques (13-18). While the tumor 
vasculature has been found to allow passive extravasation of NPs as large as 700 nm, in 
vitro experiments have shown the interstitial space to sharply limit passive motion of 
macromolecules larger than 10-15 nm in diameter (4, 18).  Computational work by Yuan 
et al. has also suggested a diameter limit of approximately 10 nm for unimpeded 
diffusion or convection-driven motion of macromolecules in the interstitium (19). 
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The same biophysical characteristics that limit the application of traditional 
therapies can be exploited to improve biodistribution using a novel approach based on 
SPM NP therapy delivery. SPM NPs can be specifically localized within a fluid filled 
cavity to the site of a lesion or target tissue by an external magnetic field.  Protein and 
carbohydrate-based biogels can be displaced or penetrated by the SPM NPs, allowing 
direct NP-target interaction.  Aggregation of SPM NPs does not pose a barrier for 
localization in a fluid or gel filled space; larger aggregate size presumably generates a 
proportionally larger magnetic force necessary to overcome gel-based barriers to 
mobility.  
Comparison of the magnetic force experienced by a 145 nm SPM NP to reported 
values of particle mobility in tissue in (20) suggests that a magnetic force on the order of 
100 fN per NP may be sufficient to overcome the barriers that inhibit NP transport (20). 
Gel and fluid can be deformed by force on the order of hundreds of pN or less (21).  
The net motive force of a SPM NP is governed by electromagnetic theory and Newton’s 
Law and is determined by the sum of forces acting on the NP including diffusion, 
convection, and an external magnetic force.  Calculation of the total force impinging on a 
single NP allows estimation of velocity and direction in a viscous medium (22). The 
diffusive force is orders of magnitude smaller than the magnetic forces that can be 
generated with SPM NPs (23).   
Ferrous oxide (Fe3O4) is among the most suitable magnetic material for use in 
biological applications due to its well-characterized behavior, low toxicity, and history of 
use in clinical applications such as MRI contrast agents (24, 25).  SPM materials respond 
to an external magnetic field as a single-domain crystal and travel along the field 
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gradient.  In the absence of an external field, a SPM material has a negligible remnant 
field.  SPM materials are ideal for use in submicron magnetic carriers because they are 
magnetically responsive to an external field but lack the capacity for autonomous 
magnetic behavior such as attraction between individual NPs. 
We hypothesize that a magnetic force applied to a SPM NP by an external magnet 
field gradient can be utilized to overcome the mechanisms that limit the transport and 
uniform distribution of antitumor therapies delivered within a gel/fluid filled cavity.  
Specifically, we seek an integrated study in which in vitro experiments are conducted 
under conditions informed by the theory of mass transport modulated by a magnetic 
force.   
 
Methodology 
 
NP Characteristics 
SPM NPs were obtained from micromod Partikeltechnologie GmbH (Germany) 
with silica surface coating (135 nm radius) and 300 MW PEG surface coating (145 and 
400 nm radius). The manufacturer reported CV of 0.42, 0.47, and 0.72, for these samples.  
The NPs had a smooth surface as observed by transmission electron microscopy.  The 
micromod NP is a Fe3O4-dextran-silica composite that consists of an inner region of 
continuous phase dextran containing Fe3O4 crystals, with an dextran-silica composite 
shell.  Fe3O4 mass per NP was uniform; percentage Fe3O4 mass composition was 75% for 
the 135 nm and 145 nm NPs and 7% for the 400 nm NPs.  The NP volumetric magnetic 
susceptibility (χV) was 0.2105 for 135 nm and 145 nm NPs and 0.0081 for 400nm NP 
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under saturating conditions (H > 7.96 x 105 A m-1). NPs with the native characteristics of 
a silica shell on the NP surface and NPs with a surface coating of 300 MW PEG were 
utilized. 
All NPs were maintained in a pH 7.6 phosphate buffered saline (PBS) solution 
consisting of:  1.9 mM NaH2PO4, 8.1mM Na2HPO4, 5.4 mM KCl, and 154 mM NaCl. 
 
Three Dimensional Mapping Of The Magnetic Field 
A 2.54 cm cube of grade 40 NdFeB magnet (National Imports) was utilized for in 
vitro measurement of nanoparticle behavior.  An equipolar xy plane on a nonpole face of 
the magnet was utilized for in vitro experiments.  The magnetic field was measured by a 
Lakeshore 421 Gaussmeter with a MMA-2502-VH Hall probe.  A three dimensional 
optical tracking system (Optotrack) was utilized to measure the position of the 
gaussmeter probe (Lakeshore) over time. The gaussmeter probe was rigidly affixed to an 
Optotrack probe mount.   The Optotrack system reported the probe’s position in space 
(X,Y,Z) and the yaw, roll and pitch of the probe.  Position and orientation measurements 
were collected every 50 ms for 10,500 samples. Measurements relative to the Optotrack 
were registered to the physical surface of the magnet by measuring the corners of the 
measured face in both physical space and in Optotrack space.  The transformation from 
the measured position of the Optotrack probe and the rigidly attached gaussmeter probe 
was calculated and applied to position data produced by the Optotrack system.  The 
magnetic field was not measured within two millimeters of the surface due to the 
gaussmeter probe design. 
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9,400 measurements of the magnetic field were retained after values collected 
when the probe was at an angle greater than five degrees off perpendicular were 
discarded.  Data within the equipolar region of the magnet surface utilized during in vitro 
experiments were averaged and characterized by field strength as a function of distance 
from the magnet surface.  
 
Extracellular Matrix Viscosity Measurement 
Extracellular matrix purified from Engelbreth-Holm-Swarm murine sarcoma was 
purchased from Sigma-Aldrich. Anton Paar was contracted to provide rheological 
characterization of the ECM gel undiluted and at 1:1 dilution with Dulbecco’s Modified 
Medium.  Briefly, samples were held at 37° C for 40 minutes following introduction into 
the cone and plate measurement chamber.  ECM gel response was measured over a shear 
ramp from 10-4 to 10-1 Hz (n=3).  Viscosity was determined to be 1.1 x 106 ± 1.5 x 105 cP 
for the undiluted sample and 4.0 x 105 ± 6.4 x 104 cP for the 1:1 diluted sample.  
 
In Vitro Visualization System 
  ECM was thawed overnight at 4° C from -70° C storage. 100 μL of extracellular 
matrix was deposited into a glass vial measuring 3.5 mm inner diameter by 3 cm height at 
4° C.  The vial was stored for 12 hours at 4° C to allow release of trapped air from the 
ECM, and then incubated for 40 minutes at 37° C to induce polymerization of the ECM 
gel.  Nanoparticle solutions were created at 1 mg mL-1, 0.250 mg mL-1 and 0.083 mg mL-
1 utilizing each nanoparticle cohort: 135 nm radius, PEG coated; 145 nm radius, silica 
coated; and 400 nm radius, PEG coated.  50 μL of 37° C NP solution in PBS was 
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sonicated for 5 s, and then introduced onto the surface of the gel.  Evaporation was 
prevented by sealing the vial with wax film.  The vial was placed on the surface of the 
magnet inside a vertical support frame.  Mean maximum ECM gel height above the 
magnet was 9.5 mm, 7.8 mm, 7.0 mm for the 400 nm radius, PEG coated; 135 nm radius, 
PEG coated; and 145 nm radius, silica coated NP cohorts, respectively. 
 Digital images of the NP location were captured using a 3 megapixel digital 
camera (Canon) equipped with a macro lens at 37° C.  Camera settings, timing, and data 
capture were remotely controlled via a personal computer and Cam4you software (Hans-
David Alkenius).  NP behavior was imaged over 24 hours.  The digital images had a 
resolution of 2020 μm2 per square pixel. 
 
Computational Data Analysis 
NP position in the ECM gel was determined by contrast measurement of leading 
edge of the NP motion in the gel.  Conversion from pixels to microns was based on 
measurement of fixed elements within the digital images.  NP velocity was calculated in 
triplicate by linear regression over a two-hour time interval spanning the median position 
measurement (d½)(r2 > 0.97).  NP position relative to the magnet surface was normalized 
within each radius/surface coating cohort. This single velocity value comparison was 
selected to provide uniform magnetic field characteristics for all samples and to minimize 
the potential influence of end effects on SPM NP mobility. 
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Electron Microscopic Imaging of SPM NPs 
The SPM NPs were imaged with a Philips CM-12, 120 keV transmission electron 
microscope.  NP samples were suspended in a negative staining solution (NanoW) and 
dried on a copper grid.  The samples were then visualized under 31,000x and 300,000x 
magnification at 80 KeV.  Images were captured with a digital imaging camera (AMT 
Digital). 
 
Theoretical Estimation of SPM NP mobility 
The primary forces influencing magnetic NP mobility in a biological system are 
the drag force (FD) and the external magnetic force (FM).  Colloidal NPs are prone to 
aggregation, particularly in a complex biological environment.  In a gel system, aggregate 
behavior may be modeled by assuming a solid sphere geometry of the aggregate radius 
and by adjusting the magnetic composition of the aggregate to accommodate the packing 
structure of the NPs in the aggregate (26). 
Holligan et al. have described a system of equations for calculating the velocity of 
SPM NPs in a tissue phantom based on the work of Zborowski (22, 27) . The magnitude 
and direction of the force FM on an SPM NP aggregate is a function of the NP volumetric 
magnetic susceptibility (χV), the volume of SPM material (Vm, m3), the gradient of the 
magnetic field (∇B, T m-1), and the magnetic field strength (B, T).  
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The maximum magnitude of the magnetic force can be calculated, when NP magnetic 
moments are aligned and the magnetic domains are saturated by the following equation: 
 
0
2
mV
M 2μ
BVχF ∇=  
    (1)
where μ0 is the permeability of free space, is 4π x 10-7 (T m A-1). 
The drag force on the aggregate at terminal velocity, FD, can be calculated as: 
 πrηv6FD =      (2)
where r is the radius of the aggregate (m), η is the viscosity the surrounding fluid (N s m-
2), and v is the aggregate velocity (m s-1).  The NPs reach their terminal velocity when 
magnetic force, FM and the drag force, FD are equal. This terminal velocity can be 
calculated from (eq. 1) and (eq. 2): 
 
rημ12π
BVχv
0
2
mV ∇=      (3)
Aggregates below 500 μm in diameter can be assumed to instantaneously reach their 
terminal velocity in a viscous fluid (e.g. a 500 μm diameter aggregate of density 2.5 g 
cm3 achieves terminal velocity in 35 ns in a 1 x 106 cP fluid) (28). 
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Figure 1. Qualitative velocity changes were observed during time lapse series images of 
NP migration in in vitro ECM gel system. Each panel contains 4 frames: 0, 1, 4.8, 22 
hours (left to right).  Panel A. 135 nm radius PEG surface coated particles (χ = 0.2104) 
B. 145 nm radius silica-coated surface particles (χ = 0.2104) C. 400 nm radius PEG 
surface coated particles (χ = 0.081). 2 mm scale bar. 
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Results 
SPM NPs were mobile in a purified extracellular matrix under guidance of an 
external magnetic field (Figure 1).  NP velocity through the gel was visually distinct 
between NP cohorts of surface coating and solution concentration.  NP surface coating 
and NP solution concentration made a qualitative difference in NP-gel interactions and 
NP mobility. Velocity of NPs with PEG surface coating was increased compared to the 
velocity of NPs with a silica coating. In the absence of a magnetic field, NPs showed 
slight accumulation at the aqueous-gel interface over 24 hours; NPs did not enter the gel 
in the absence of a magnetic field. 
145 nm radius PEG coated NPs achieved a d½ velocity of 1.5 ± 0.71 mm hr-1 
(mean ± SD), seven times greater than the d½ velocity of 135 nm radius silica coated NPs 
of equivalent magnetic response (0.21 ± 0.07 mm hr-1) (Figure 2).   The larger 400 nm 
radius PEG-coated NPs had a velocity of less than 0.01 mm hr-1 and never achieved the 
d½ position.  The three surface coating / size NP cohorts had statistically significant 
difference between their mean velocities. 
SPM NP velocity increased as a function of NP solution concentration.  NP 
solution concentrations of 1000 μg mL-1, 250 μg mL-1, 83 μg mL-1 migrated through the 
ECM gel at 1.5 ± 0.71 mm hr-1, 0.27 ± 0.15 mm hr-1, 0.087 mm hr-1 ± 3.5 x 10-4 mm hr-1, 
respectively (Figure 3).  NP mobility increased with concentration over the range from 
83.33 μg mL-1 to 1000 μg mL-1. 
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 Figure 2. Increased NP velocity at smaller radii and with PEG coating. Panel A. NP 
aggregate leading edge position as a function of time based on normalized distance. 50 
μL of 1 mg mL-1  135 nm silica, 145 nm PEG coated and 400 nm PEG coated NP 
solution mobilities are plotted with linear regression underlay (n=3).  Panel B. Mean 
velocity measurement for each NP cohort over two-hour time interval spanning the 
median position measurement (d½)(n=3).  Error bars represent standard deviation.  
P=0.004 for all comparisons by Kruskal-Wallis One Way ANOVA on Ranks. 
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Figure 3.  Increasing concentration of NPs resulted in increased mean aggregate velocity. 
Bulk mobility of 145 nm PEG coated SPM NPs increased with initial concentration.  
Mean velocity for each cohort over the two-hour time interval spanning the median 
position measurement (d½) is shown as a function of initial NP concentration (n=3).  
Error bars represent standard deviation. P=0.001 for all comparisons by Kruskal-Wallis 
One Way ANOVA on Ranks. 
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NP mobility estimated from theory (eq. 3) correlated well with the movement of 
145 nm radius PEG-coated NP through the extracellular matrix. Plotting aggregate 
velocity (eq. 3) over the range of experimentally observed aggregation diameters and 
literature-supported fractal aggregate packing densities (φm), the velocity range (0 - 2.8 
mm hr-1) matches the observed velocity of 145 nm radius PEG-coated NPs (1.5 ± 0.75 
mm hr-1) accurately (Figure 4).  The upper limit of packing density (φm = 0.15), was set 
by previous reports of fractal aggregate formation from NPs in solution (29).   The 145 
nm radius PEG-coated NP aggregate was determined to generate a force of 
approximately 750 μN (eq. 1). 
The magnetic field was uniform over the xy plane of NP mobility analysis. The 
permanent magnetic utilized in this study generated a magnetic field between 100 mT 
and 500 mT over the height of the ECM gel contained in the glass vial.  The magnetic 
field gradient in this range was 45 T m-1 (Figure 5).   
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Figure 4. Theoretical nanoparticle aggregate velocity as a function of aggregate diameter 
and aggregate volume occupied by nanoparticles (φm).  Velocity is calculated based on 
experimental values in Figure 2 (50 μL volume of 1 mg mL-1 145 nm diameter 
nanoparticles, CV 0.47), Figure 5. (0.3 T magnetic field, 45 T m-1), manufacturer 
supplied values (χ = 0.2104), and Anton Paar contract testing (η = 1x106 cP). Solid 
contours indicate 1 mm hr-1 increments; dashed lines correspond to 0.25 mm hr-1 
increments.  Percent occupied volume limited by fractal aggregate packing efficiency 
values from Tseng et al. (14.6%) (29). 
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Figure 5. Magnetic field strength in the Z direction (inset, barbell) of a XY plane (inset, 
hashed region) corresponding to the experimental region.  Dashed line (left) corresponds 
to the interior bottom of the glass vials utilized in this study.  Dotted line (right) 
corresponds to the maximum ECM gel height.  Data below 2 mm was unavailable due to 
gauss meter probe design. 
40 
Discussion 
 The greatly reduced ECM adhesion of the 145 nm PEG surface-coated NPs 
demonstrates the utility of this system for characterizing NP interactions in a biological 
environment.  The inability of the larger, 400 nm radius, PEG surface-coated NPs of 
equivalent per NP magnetic susceptibility to enter the ECM gel suggests a balance 
between passive resistive forces in the ECM matrix and the induced magnetic force.  
Further analysis of the balance between magnetic and passive forces can set the limits for 
maximum NP size as a function of NP magnetic susceptibility. 
Minimizing surface interactions between nanoparticles and the surrounding 
environment has become an essential element in development of advanced therapeutics 
and other nanoscale structures for in vivo applications. Advanced surface coatings such as 
ethylene oxide-propylene oxide block copolymers (e.g. Pluronic®) and PEG coatings 
pose a means to minimize nanoparticle aggregation and adhesion to the extracellular 
matrix (30). The silica-dextran surface of the 270 nm nanoparticles appears to induce 
aggregation and/or nonspecific binding to components in the extracellular matrix. These 
binding events are mediated by hydrophobic/hydrophilic interactions and charge-charge 
interactions.  Modulation of SPM NP mobility mediated by surface characteristics 
suggests this system as a sensitive method to assess nanoscale surface phenomena in 
biological systems. 
Our quantitative in vitro system allowed measurement of superparamagnetic 
nanoparticle velocity at a distance of 1 to 10 mm from the magnet.  Superparamagnetic 
nanoparticles traversing this distance experience a continuously varying magnetic field 
strength from 500 mT to 100 mT.  The mathematical representations in equations 1 and 3 
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accommodate the changing magnetic field strength with position in estimating the SPM 
transport characteristics through the model extracellular matrix. 
We expect that the range of magnetic field strengths used in this work will be the 
upper bound of values appropriate for clinical applications. FeRx, a company that 
conducted extensive in vivo trials with doxorubicin coated magnetic microparticles 
(MTC-DOX), utilized a 5 T magnetic field source.  Based on the known decay of the 
magnetic field with distance, the FeRx clinical apparatus has a field strength of 
approximately 200 mT and a magnetic field gradient of 15 T m-1 at a the mean 
therapeutic depth of 11 cm (31). These values correspond well with the values studied in 
this work. 
The theory-driven estimation of NP velocity supports magnetically induced motion 
within gel and fluid filled cavities.  The predicted velocity of the aggregate suggests a 
low-density structure.  Tseng and Kulkarni have separately characterized nanoparticle 
and microparticle aggregates at maximum densities of 14.6% and 13% (29, 32) in fractal 
packing systems. Magnetic particles in an external field have been shown to form low-
density fractal aggregates due to their anisotropic interactions (33).  The data presented in 
this study were consistent with literature reports that fractal aggregate density increases 
as a function of colloid concentration (33).  Smaller, less dense aggregates had 
substantially lower velocity (Figure 3), as predicted by our system of equations (Figure 
4). 
The permeability of fractal aggregates to fluid flow is not fully understood.  Kim 
et al. have proposed that fractal aggregates perform as a sphere with quadratically 
increasing permeability from the aggregate center (34).  In contrast, Li et al. have 
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characterized macroscale pore diameter to be on the order of 1/9 the fractal aggregate 
diameter (35).  The system explored in this work allows the study of particle dynamics in 
a gel system that differs from the aqueous systems utilized by Kim and Li.  We 
hypothesize that the components of the ECM are too large to pass through the pores in 
the growing aggregate without interacting with and binding in the tortuous pores of the 
aggregate.  The primary components of the ECM gel are near the size of the individual 
SPM NPs utilized in this system:  collagen (fiber, 280 nm), laminin (cruciform, 77 nm x 
42 nm), and proteoglycans (fiber, 100 - 170 nm) (36-38) .   These features combine to 
cause the SPM NP aggregate to behave as a solid object when interacting with the ECM 
gel.   
 Although aggregation is a potential barrier to application of nanoparticles 
interstitially, the mobility of magnetic nanoparticles in gel and fluid filled cavities is not 
compromised by aggregation.  Cavity mobility of NPs can be enhanced by NP surface 
coatings that further diminish gel adhesion and by linkage of enzymes to NPs to degrade 
the protein networks that restrict motion.  Theoretical estimation of nanoparticle and 
aggregate mobility will assist in identification of the optimal NP properties for 
magnetically induced motion in cavities.   
 Magnetically driven dispersion of NP therapeutic carriers holds promise for 
varied applications such as treatment of abdominal cancer metastasis, spinal lesions, and 
sputum thinning in cystic fibrosis patients.  We have demonstrated the ability of SPM 
NPs to migrate through the gel and fluid barriers that are common in these applications.  
Optimization of NP mobility in a biological cavity can be achieved by selection of NPs 
informed by the theoretical equation set and tested in the in vitro ECM gel system 
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described in this work.  This work seeks to model in vivo conditions and examines SPM 
NP mobility in undiluted purified ECM as a surrogate for the rheological characteristics 
of ECM.  The calculational methods described in this work are suitable for prediction of 
SPM NP mobility in less viscous materials. This experimental system is especially useful 
for determining the impact of surface coating, size and magnetic response on NP mobility 
in a biological context.   
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 Abstract 
Steric barriers such as collagen I sharply limit interstitial delivery of 
macromolecular and nanoparticles based therapeutic agents.  Collagenase-linked 
superparamagnetic NPs overcame these barriers and moved through in vitro extracellular 
matrix (ECM) at 90 μm hr-1, a rate similar to invasive cells, under the influence of a 
magnetic field. NP migration in ECM diminished linearly over five days.  The 
collagenase-NP construct overcame two of the most significant barriers to nano- and 
microscale therapeutics deployment:  proteolytic enzyme stability was maintained during 
a clinically useful time frame by immobilization on the nanoparticle surface and 
degradation of interstitial barriers to tissue biodistribution was enabled by the conjugated 
microbial protease. 
 
Introduction 
Nanoscale and microscale therapeutic structures have poor mobility when 
administrated to tissue interstitium.  Clinical application of gene therapy, bioactive 
proteins and other large molecular therapeutics are often limited by geometric effects 
such as steric barriers, negligible diffusion, and poor interstitial convective mobility (1, 
2). Viscous nonspecific molecular and physical interactions with tissue components also 
restricts transport and further limits the efficacy of these novel therapeutic structures (3, 
4). 
 We propose to overcome these limits to nanoscale and microscale therapeutic 
tissue distribution by development of a protease-functionalized superparamagnetic 
nanoparticle (SPM NP) vehicle.  The magnetic character of the SPM NP provides spatial 
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 and temporal control of NP localization in the interstitial space using an external 
magnetic field to facilitate intratissue mobility (5, 6).  A surface-linked protease enables 
degradation of adhesive and steric barriers in the interstitial space (7, 8). 
Protease degradation of biological barriers is a common strategy employed by 
motile and invasive cells. Involvement of a broad spectrum of matrix metalloproteinases 
in metastasis has been documented, including various collagenases (9, 10). Migrating 
neural crest cells in embryos utilize matrix metalloproteinase-type 2, tissue plasminogen 
activator, and urokinase plasminogen activator to migrate to the developing neural crest 
(11, 12). Embryo implantation following fertilization is marked by dramatic increase in 
protease secretion (13). Pathogenic microorganisms and viruses, including S. pyogenes, 
Human papillomavirus,  P. insidiosum, and P. aeruginosa secrete proteases or  induce the 
release of endogenous proteases as an invasive mechanism in host tissues (14-17).  
Reported literature values for in vitro cell migration rates through purified extracellular 
matrix substrates average 104 ± 44 μm h-1 (4 to 434 μm h-1) (18-20), a rate that is 
consistent with a significant increase in tissue biodistribution of large molecules and 
nanoparticles.  
 While collagenase is an approved salve by the United States Food And Drug 
Administration for tissue debridement, exploration of proteases for enhanced interstitial 
mobility is still an emerging area of study.  Netti et al., for example, documented a two 
fold increase in diffusion rates of antibodies following in situ collagenase treatment of 
rigid human glioblastoma (U87) and human soft tissue sarcoma (HSTS 26T) tumors (7). 
Nanoparticle platforms enable development of multifunctional therapeutic 
vehicles. Intrinsic material properties such as superparamagnetism or x-ray opacity can 
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 be combined with surface modifications that minimize nonspecific interactions with 
biological structures (21, 22). The NP surface can be further modified with therapeutic 
structures ranging from small drug molecules to large gene therapy constructs (23, 24).  
The mobility of polyethylene glycol (PEG)-coated SPM NPs with surface-
attached collagenase was studied in a quantifiable in vitro interstitial model that consisted 
of purified extracellular matrix and collagen I.  Collagenase-linked NPs had enhanced 
mobility through purified extracellular matrix/collagen I alloy gels.  The covalent 
collagenase-NP construct allowed temporal and spatial localization of the enzymatic 
function by an external magnetic field.  This quantitative system of construction and 
analysis of protease-nanoparticle mobility in purified extracellular matrix components 
may provide a useful tool to discretely characterize and model many invasive biological 
processes. Protease-functionalized NPs may enhance the distribution and delivery of 
macromolecular therapeutics within targeted tissues such as neoplastic disease that are 
transport limited. 
 
Methodology 
 
NP Characteristics 
SPM NPs were obtained from micromod Partikeltechnologie GmbH (Germany) 
with 300 Da PEG surface molecules (145 nm radius). The manufacturer reported a 
diameter CV of 0.47.  The NPs had a smooth surface as observed by transmission 
electron microscopy.  The NP was a Fe3O4-dextran-silica composite of an inner 
continuous phase dextran containing Fe3O4 crystals and a dextran-silica composite shell.  
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 The PEG terminus was a primary amine group or carboxylic acid group.  Percentage 
Fe3O4 mass composition was 75%. The NP volumetric magnetic susceptibility (χV) was 
0.2105 for under saturating conditions (H > 7.96 x 105 A m-1).   
 
Conjugation of bovine serum albumin (BSA) to NP 
 SPM NPs with a PEG-carboxylic acid surface were conjugated to bovine 
serum albumin (BSA) by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDAC) / N-hydroxysuccinimide (NHS) reaction (Pierce) (25).  5 mg of SPM NP were 
incubated at 25 ºC for one hour in 0.5 mol L-1 2-(N-morpholino)ethanesulphonic acid 
(MES) buffer adjusted to pH 6.3 by Na2CO3 containing 600 μg EDAC and 1.2 mg NHS. 
The activated SPM NPs were magnetically washed into 0.1 mol L-1 MES buffer 
containing 50 μg BSA and incubated for three hours. Remaining activated groups were 
blocked by addition of 50 μL 25 mmol L-1 glycine with continued incubation for 30 
minutes.  The NP-BSA conjugates were magnetically washed three-fold into 1.0 mL of 
0.1 mol L-1 sodium phosphate, 0.15 mol L-1 NaCl pH 7.2 buffer (PBS).  Purity of the NP-
BSA conjugates was measured by sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis. Protein quantity in each lane was calculated based on a standard curve 
generated from total band intensity in lanes containing known amounts of BSA (r2 > 
0.89). Total conjugated BSA per NP was calculated by subtraction of BSA in the two 
terminal washes and subtraction of protein that was removed by incubation of the 
conjugate with 10% weight per volume SDS in water, pH 9.0 for 30 minutes from the 
known starting quantity of BSA. 
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 Sulfhydryl modification of collagenase 
 Sulfhydryl groups were introduced to the surface of collagenase using N-
succinimidyl-S-acetylthiopropionate (SATP, Pierce) based on the method described by 
Duncan et al. (26). Collagenase (4 mg) purified from C. histolyticum (CLSPA, 
Worthington Biochemical) was dissolved in 1.0 mL of PBS buffer. SATP (2.9 mg) were 
dissolved in 20 µL DMSO and incubated with the collagenase solution at 25 °C for 30 
minutes.  SATP labeled protein was purified by four-fold centrifugal separation with 50 
kDa cutoff filters (Amicon). Acetyl protective groups were removed by incubating the 
labeled protein in a solution containing 0.5 mol L-1 hydroxylamine, 25 mmol L-1 EDTA 
in PBS, pH 7.2 for two hours at 25 °C. Sulfhydryl-modified protein was purified from 
hydroxylamine by four-fold centrifugal separation with 50 kDa cutoff filters (Amicon).  
Collagenase concentration was analyzed by absorbance at 280 nm. 
 
Quantification of SH labeling efficiency 
 Sulfhydryl groups on the surface of the protein were quantified by Ellman’s 
Method (27).  Samples of collagenase were prepared in 0.1 mol L-1 sodium phosphate, 1 
mmol L-1 EDTA buffer, pH 8.0.  Four milligrams of 5,5'-Dithio-bis-(2-nitrobenzoic 
acid)(DTNB, Pierce) were dissolved per milliliter of buffer.  The DTNB solution was 
diluted 1:50 into a 1:10 sample dilution and reacted for 15 minutes at 25 ºC.  Absorbance 
at 412 nm was measured and concentration of colored reactant was quantified based on a 
14150 M-1 cm-1 molar extinction coefficient. Collagenase concentration was analyzed by 
absorbance at 280 nm. 
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 Heterobifunctional linker modification of SPM NP surface 
 Primary amines on the surface PEG groups of the SPM NPs were modified to 
form a maleimide reactive group.  The heterobifunctional crosslinker, sulfosuccinimidyl 
4-[N-maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC, Pierce) was utilized to 
bind the sulfhydryl modified collagenase to the PEG groups on the SPM NP in a 
variation of the method described by Duncan et al. (26).  SPM NPs (400 mg) in 0.1 mol 
L-1 sodium phosphate, 2.5 mmol L-1 EDTA buffer, pH 7.4 were mixed with 2 mg Sulfo-
SMCC in an inverting mixer at 37 ºC for 30 minutes.  Sulfo-SMCC modified NPs were 
magnetically washed four times (1 x 106 dilution of reactant) into 0.1 mol L-1 sodium 
phosphate, 10 mmol L-1 EDTA buffer, pH 7.4. 
 
Collagenase-nanoparticle conjugation 
 Sulfhydryl labeled collagenase was mixed with 2 mg sulfo-SMCC modified NPs 
by inversion in 0.1 mol L-1 sodium phosphate, 10 mmol L-1 EDTA buffer, pH 7.4 at 4º C 
for 12 hours at a 10,000:1 molar ratio.  Unconjugated collagenase was removed by 
magnetically washing the nanoparticles four times (1 x 106 dilution of reactant) into 0.1 
mol L-1 sodium phosphate, 10 mmol L-1 EDTA buffer, pH 7.4. 
 
Enzymatic activity assay 
Collagenase activity was assayed by fluorescence production from a dye-
quenched gelatin substrate (Invitrogen) at 25 ºC.  The assay was linear over an enzyme 
activity range from at least 0.01 U mL-1 to 0.1 U mL-1 when conducted using dilutions 
from a collagenase standard of manufacturer-characterized activity (Worthington 
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 Biochemical). One unit released one micromole of L-leucine equivalents from collagen I 
in five hours at 37 °C, pH 7.5.  NP attenuation of fluorescence from the fluorogenic 
substrate was corrected with an attenuation standard curve of fluorescence signal 
intensity of 0.5 U/mL collagenase with concentrations of SPM NPs from 10 μg mL-1 to 
1000 μg mL-1.  Experimental values for functional collagenase molecules per NP were 
calculated based on a standard curve of collagenase concentrations of known activity and 
NP optical attenuation. 
 
Three Dimensional Mapping Of The Magnetic Field  
An equipolar xy plane on a nonpole face of a 2.54 cm cube of grade 40 NdFeB 
magnet (National Imports) was utilized for in vitro measurement of nanoparticle 
behavior. The magnetic field was measured by a Lakeshore 421 Gaussmeter with a 
MMA-2502-VH Hall probe as previously described (28).  Data within the equipolar 
region of the magnet surface utilized during in vitro experiments were averaged and 
characterized by field strength as a function of distance from the magnet surface. The 
magnetic field was uniform over the xy plane of NP mobility analysis. The permanent 
magnet utilized in this study generated a magnetic field between 100 mT and 500 mT 
over the height of the alloy gel contained in the glass vial.  The magnetic field gradient in 
this range was 45 T m-1. 
 
In Vitro Visualization System 
  The in vitro visualization system extended previous efforts to include the 
formation of collagen I-supplemented gels (28-30). Purified ECM was thawed overnight 
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 at 4 °C from –70 °C storage. Collagen I was prepared at 0.36 mg mL-1 in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 30 mmol L-1 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid, 5.4 g mL-1 NaHCO3 at pH 7.2.  Purified ECM was 
mixed 1:4 with collagen I solution to form an alloy gel. 80 µL of alloy gel were deposited 
into a glass vial measuring 3.5 mm inner diameter by 3 cm height at 4 °C.  The vial was 
stored for at least 2 hours at 4 °C in a sealed microfuge tube to allow release of trapped 
air from the alloy gel, and then incubated for 40 minutes at 37 °C to induce 
polymerization.  Nanoparticle-conjugate solutions were created at 1000 μg mL-1.  50 μL 
of 37° C NP solution in 50 mmol L-1 Tris-HCl, 150 mmol L-1 NaCl, 5 mmol L-1 CaCl2, 
200 μM sodium azide, pH 7.6 was sonicated for 5 s, and then introduced onto the surface 
of the alloy gel.  The vial was sealed with wax film to minimize evaporation.  The vial 
was placed on the surface of the magnet inside a vertical support frame.  Mean maximum 
alloy gel height above the magnet was 8 mm. 
 Digital images of the NP location were captured using a 3 megapixel digital 
camera (Canon) equipped with a macro lens at 37 °C as previously described (28). 
Camera settings, timing, and data capture were remotely controlled via a personal 
computer and Cam4you software (Hans-David Alkenius).  NP behavior was imaged over 
24 hours.  The digital images had a resolution of 2020 µm2 per square pixel. White 
incandescent lighting was used for particle mobility assays.   
 
Computational Data Analysis 
NP position in the alloy gel was determined by contrast measurement of leading 
edge of the NP motion in the gel as previously described (28).  Conversion from pixels to 
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 microns was based on measurement of fixed elements within the digital images.  NP 
velocity was calculated in triplicate by linear regression over a two-hour time interval 
spanning the median position measurement (d½)(r2 ≥ 0.89).  This single velocity value 
comparison was selected to provide uniform magnetic field characteristics for all samples 
and to minimize the potential influence of end effects on SPM NP mobility. 
 
Results 
 
Enhanced Conjugate Mobility Through ECM 
Collagenase-NP conjugates migrated through the alloy gel at a rate of 90 ± 28 μm 
hr-1.  The NP conjugates rapidly accumulated at the aqueous-gel interface under the 
influence of the external magnetic field.  The layer of NP conjugates subsequently 
condensed over approximately one hour to form a spherical concentrate on the order of 
300 μm in diameter before migrating further into the gel. Mobility of the collagenase-NP 
particles in the gel was positively correlated with the number of collagenase molecules 
per NP (Figure 1, Figure 2). BSA-NP conjugates, lacking proteolytic activity, remained 
in a layer at the aqueous-gel interface and did not enter the alloy gels over the course of 
24 h.   
 
Stability of Conjugate Enzymatic Function 
Collagenase conjugated to SPM NPs demonstrated substantially enhanced 
functional stability compared with collagenase in solution at 4 ºC (Figure 2, Figure 3).  
The activity of free solution collagenase decayed in an exponential fashion with a half-
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 life of 12 hours.  Proteolytic function of the collagenase-NP conjugate decayed linearly, 
losing 50% of the initial enzymatic activity after 48 hours.  
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Figure 1.  Mean magnetic field induced velocity of proteolytic nanoparticle (■) 
mobility through alloy gel decreases over the course of five days. BSA conjugate NPs 
(∇) and native PEG-coated NPs (●) have minimal mobility in the alloy gel. 
Collagenase-NP conjugates were tested on sequential days for mobility through the 
alloy gel substrate.  Data are mean value ± std.dev. of NP velocity over 8 h; n > 3. 
The solid line is a linear regression approximation of the proteolytic nanoparticle 
velocity as a function of time since conjugation (r2 = 0.89). Error bars < 0 µm h-1 are 
truncated. 
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Figure 2.  Collagenase bound to the surface of the NPs demonstrated sustained 
activity over a linear decay pattern during storage at 4 ºC. Data are mean value ± 
std.dev.; n = 6 (except for t = 5 where n = 3). Vertical error bars are std. dev. of data; 
horizontal error bars are std. dev. of similar time points.  Error bars < 0 functional 
enzymes NP-1 are truncated. The solid line is a linear regression approximation of 
proteolytic activity as a function of time since conjugation (r2 = 0.73). 
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Figure 3.  Collagenase free in solution decayed rapidly to less than ten percent of the 
original activity in 1.5 days.  Enzymatic activity of collagenase stored in PBS, pH 7.2 at 4 
ºC was measured with a fluorogenic gelatin substrate.  Inactivation / degradation occurred 
following an exponential pattern characterized by: enzymatic activity = 0.498e-1.654t, r2 > 
0.99.  Data are mean value ± std.dev. n = 3.  Horizontal error bars reflect averaging of 
data from similar time points. Error bars < 0 U mL-1 are truncated.  Collagenase 
conjugated to the NP surface (○) had an enhanced functional lifetime relative to free 
collagenase in solution (●)(inset); mean values normalized to  t = 0 value.   
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 Collagenase-NP Conjugation 
Collagenase activity was not significantly affected by sulfhydryl modification up 
to ten sulfhydryls per collagenase (Figure 4). The number of sulfhydryls applied per 
collagenase was controllable by reaction stoichiometry and saturated above 
SATP:collagenase molar ratios of 50:1 at nine sulfhydryl groups per collagenase.  
NP-collagenase conjugation reached a maximum level of 490 functional enzymes per NP 
after 1.25 hours of reaction (Figure 5).  The number of functional enzymes applied to the 
NP surface was controllable through selection of the reaction time with half of the 
maximum surface functionalization occurring at 11 minutes of incubation.  Control 
reactions between SATP modified collagenase/native NP, native collagenase/sulfo-
SMCC modified NP, and native collagenase/native NP had negligible collagenase 
activity after one hour of reaction (Figure 5). 
 
Available Surface Groups For Modification 
Each NP had 1550 ± 130 reactive primary amine groups. The number of surface 
reactive groups was calculated by reaction of native NPs with SATP, deacetylation, then 
reaction with Ellman’s Reagent (27).  Spectroscopic analysis of the Ellman’s reaction 
was conducted on the solution phase of the reaction following magnetic separation of the 
SPM NPs.   
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Figure 4.  Collagenase function was undisturbed by saturation SATP modification, up to 
10 sulfhydryl additions per collagenase (A).  Surface-available sulfhydryl groups allowed 
cross-linking of the active collagenase to the amine SPM NP surface through the 
maleimide/NHS hetero-bifunctional linker, sulfo-SMCC.  The result was active 
collagenase enzyme conjugated to the SPM NP surface.  The number of sulfhydryl 
groups applied per collagenase molecule is controllable by reaction stoichiometry.  (B) 
SATP addition of sulfhydryl groups to collagenase saturated above a 50:1 molar ratio at 9 
sulfhydryl groups per collagenase, SH groups = 9.21(1 - e-0.062(Molar Ratio)),    r2 > 0.89.  
Native collagenase had 0.9 ± 1.4 sulfhydryl groups per enzyme molecule. Sulfhydryl per 
collagenase values are rounded up to nearest whole integer value from mean in panel A. 
Data are ± std.dev of measurements or trials.  Panel A: n = 1 except 1 and 8 sulfhydryl 
groups where n ≥ 3. There were no significant differences in collagenase activity among 
the various sulfhydryl treatments (P = 0.069 by one-way ANOVA, no significant 
difference).  Panel B: n = 1 except 0:1 and 250:1 SATP:collagenase molar ratios where n 
≥ 3.  
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Figure 5. Surface conjugation of collagenase to NPs was modulated by temporal control 
of binding kinetics. SATP modified collagenase was reacted with Sulfo-SMCC modified 
NH2-PEG NPs at a 10000:1 molar ratio ( ).  Native NPs reacted with SATP activated 
collagenase (●), SMCC activated NPs reacted with native collagenase (▼) and native 
NPs reacted with native collagenase (■) all had minimal functional activity.  Collagenase 
activity of all samples was characterized by cleavage of fluorogenic gelatin.  The reaction 
was essentially complete at t = 1.25 h and was half-maximal at t = 0.2 h.  Horizontal axis 
is broken for 4.5 h < t < 17.5 h to improve clarity.  Each data point is mean value ± 
std.dev.; n = 4 except n = 2 for unreactive controls.  Horizontal error bars reflect 
averaging of data from similar time points.  Control populations were evaluated at one 
hour but are horizontally offset for clarity.  Regression plot excludes data t > 10 h where 
free-solution inactivation / degradation of collagenase is evident (Figure 3).  Number of 
attached enzymes = 491(1-e-3.75t). 
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 BSA-NP Conjugation 
2.6 ± 0.3 μg and 0.8 ± 1.0 μg of BSA were bound per mg NP, for activated and 
native NPs, respectively. EDC/NHS BSA-NP conjugation yielded 9.2 ± 1.0 μg (mean ± 
std dev; n=3) of residual free BSA in the sham set (lacking NHS/EDC) and 7.5 ± 0.5 μg 
(mean ± std dev; n=3) of residual free BSA in the experimental set per mg NP in three 
separate trials.  10 μg of BSA were available in each reaction.  
 
Discussion 
The collagenase-NP construct overcomes two of the most significant barriers to 
nano- and microscale therapeutics deployment:  immobilization on the surface of the 
nanoparticles increases the stability of the enzyme during a clinically useful time frame 
and conjugation of microbial proteases allows degradation of interstitial barriers to tissue 
biodistribution.  The combination of reduced tissue resistance, magnetically controllable 
motion, and extended proteolytic lifetime yield a novel, multifunctional nanoscale 
construct with potential applications in vitro and in vivo.  Alloy gel mobility of the 
proteolytic NPs followed a similar temporal trend to the functional activity of the 
collagenase-NP conjugates, supporting the presumed structure-function relationship 
(Figure 1, Figure 2).    
SPM NPs lacking proteolytic activity, but otherwise identical to the collagenase-
functionalized SPM NPs, were unable to enter the alloy gel under the influence of the 
applied magnetic force. In the absence of surface collagenase, SPM NP in vitro mobility 
through similar ECM gels has been shown to be modulated by NP diameter (28).  While 
it has been previously shown that surface modification of similar NP carriers has a 
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 substantial impact on NP mobility, 300 Da PEG and BSA surface coatings did not allow 
mobility of NPs through the alloy gels (control sets, Figure 1) (28). The lack of mobility 
and collagenase activity of control NP populations reinforces the role of conjugate 
collagenase activity in both systems. This behavior mimics the lack of tissue distribution 
observed for nanoscale and microscale therapeutics such as gene therapy vehicles (1).  
The lack of nonproteolytic SPM NP motion through alloy gel is also consistent with 
previous unsuccessful practical applications of magnetically guided delivery in vivo (31).  
Results here suggest that the quantitative in vitro system accurately reflects the in vivo 
environment and that proteolytic surface functionalization sufficiently increases NP 
mobility to enable magnetically guided delivery in vivo. 
Therapeutic nanoparticle administration to the tissue interstitium has unique 
applications for the treatment of cancer, but is currently limited by intratissue transport 
obstacles.  Proteolytic surface functionalization may provide an approach to disbursing 
viral and nonviral gene therapy constructs or conventional therapeutics within neoplasms.  
The homogeneity of microscopic dosimetry for radiopharmaceuticals, for example, may 
be improved by controlled dispersion of radiopharmaceuticals incorporated into 
proteolytic carriers.  
Therapeutics carried by proteolytic SPM NPS and delivered by direct injection 
have access to 300 percent greater tissue volume than immobile agents.  Presuming 
characteristics compatible with clinical application and an initial 0.52 cm3 spherical 
injection volume, NPs migrating unidirectionally toward a magnetic field source would 
distribute through a tissue volume of 2.35 cm3 (+350%) over 24 hours. This enhancement 
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 in treatment volume would substantially lower the number of initial seed points necessary 
for otherwise immobile therapeutics and improve the biodistribution of the agent. 
The ability to modulate collagenase activity on the NP surface offers an 
opportunity to mimic the characteristics of many important complex biological events 
that depend on proteolysis. Freshly prepared proteolytic SPM NP mobility through the 
alloy gel averaged 90 ± 28 mm hr-1, comparable with literature values for the velocity of 
proteolytically-mediated cell invasion (104 ± 44 mm hr-1) (18-20).  This velocity 
reinforces the utility of proteolytic SMP NPs as models for cancer metastasis, neurite 
outgrowth, bacterial colonization and other invasive processes.  Quantitative, decoupled 
study of matrix metalloproteases directly implicated in metastatic shedding from primary 
site cancer would be an ideal system to screen pharmaceutical agents that interfere with 
protease-driven metastatic events. Mobility of the proteolytic SPM NPs can be modulated 
through multiple, independent mechanisms (e.g. NP size, enzyme species), allowing for 
accurate representation of cell migration in many systems.   
The covalent reaction chemistry of surface conjugation produced a construct with 
robust proteolytic activity that is not easily dissociable from the NP surface under 
biological conditions.  Previous efforts to construct enzyme-nanoparticle conjugates have 
focused on nonspecific adsorption and enhanced longevity of the enzyme (32, 33).  
Covalent conjugation restricts undesirable nonspecific release and transport of material to 
distant locations, an important characteristic for clinical application (34).   
Surface conjugation in this nanoscale system alters the enzyme inactivation 
kinetics from exponential to linear (Figure 2, Figure 3).  This transition contributes to the 
extended functional half-life of collagenase and is presumably related to reduced 
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 collagenase-collagenase access in the surface conjugated arrangement.  Quantification of 
the decay behavior of the enzyme-NP conjugates can be leveraged to attenuate 
proteolytic activity in a predictable fashion (Figure 2).   
The maleimide-sulfhydryl NP conjugation strategy is compatible with most 
proteins and biomolecules.  This flexibility creates the possibility of multifunctional 
nanoparticles incorporating a variety of lytic enzymes that degrade a wide spectrum of 
biological barriers, or a construct that has therapeutic moieties in addition to mobility-
enhancing components. The NP substrate surface area is also a powerful control element; 
spherical surface area is proportional to diameter to the second power, enabling a SPM 
NP with twice the diameter to bind four times the number of surface groups. 
The conjugation yield for the BSA- and collagenase-NP conjugates achieved in 
this work exceeded the manufacturer’s specification of 1.75 ± 0.25 μg of protein per mg 
NP at 2.6 ± 0.3 μg BSA per mg NP and 6.9  ± 1.7 μg of total collagenase per mg NP.  
However, the number binding sites per NP was experimentally determined to be 1550  ± 
130, suggesting a maximum binding capacity of 10.2 ± 0.9 μg protein per mg NP. 
Activity assays indicated approximately 500 functional collagenase molecules per NP 
after 1.25 hours of conjugation.  Random enzyme orientation during covalent linkage was 
assumed to result in a maximum of 50 percent active collagenase (3.45 μg) on the NP 
surface.  Differences in protein mass bound per NP between BSA and collagenase may 
have resulted from greater efficiency of the maleimide-sulfhydryl reaction chemistry than 
the NHS/EDC reaction chemistry. Nonspecific binding, while present in the BSA 
NHS/EDC synthesis, did not generate functional collagenase-NP conjugates with 
partially activated substrates (control sets, Figure 5). 
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Abstract 
Nanoparticle (NP) platforms offer the opportunity to develop a unified synthesis 
method for formation of multifunctional agents.  Multifunctional NPs mimic complex 
invasive biological processes found in metastatic invasion and immune cell interaction.  
We have demonstrated a facile method of conjugating multiple enzyme species to a NP 
via sulfhydryl-maleimide reaction chemistry. Horseradish peroxidase, α-glucosidase, and 
collagenase were conjugated to a superparamagnetic nanoparticle with a functional 
enzyme:NP ratio of 15:127:103:1, respectively. SATP-mediated addition of sulfhydryl 
groups to each enzyme was achieved without significant reduction in enzymatic activity.  
Conjugation of all three enzymes was accomplished using a maleimide reactive group 
generated from activation of a primary amine associated with a 300 Da polyethylene 
glycol molecule on the NP surface.  Cross reactivity of enzymes between enzyme activity 
assay systems was negligible. 
 
Introduction 
Biological systems utilize cooperative sets of enzymes, ligands and other surface 
groups to accomplish complex biological tasks ranging from multiligand T-cell 
interaction with antigen presenting cells to metastatic invasion (1-3).  Current physical 
models can only offer a limited scope of this diversity of function due to the inherent 
difficulty in developing synergistic effect when the components of these complexes are 
analyzed independently.  Nanoparticle platforms utilizing a uniform synthesis strategy 
allow creation of multifunctional systems that can generate the biologically relevant 
synergistic effects. 
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Multifunctional biomolecules have been generated for analytical and clinical 
applications, but the construction relies on unique synthetic strategies tailored to linkage 
of individual elements into a larger construct such as antibodies that have multiple 
functional ligands attached to their Fc region, or a ligand and a reporter enzyme, such as 
horseradish peroxidase (4). The necessity of customizing the synthetic assembly of these 
multifunctional therapeutic structures makes development lengthy and financially 
burdensome. The ability to translate a protocol for development of a specific 
multifunctional biomolecular construct to a generalized approach has been further 
complicated due to substantial variability in the placement of intrinsic reactive groups on 
the functional protein’s surface (e.g. an enzyme or antibody) and variability in the impact 
of modification of those units on protein function (5). 
Historically, surface functionalization by enzymes has been achieved primarily by 
nonspecific adsorption of the enzymes to solid supports (6-8). Nonspecific adsorption 
relies on poorly characterized elements of the ligands and particle supports such as total 
surface charge, hydrophobicity or van der Walls interactions, making reproducible and 
well characterized conjugation problematic (9). Nonspecific interaction binding may also 
lead to unpredictable and uncontrolled release of ligand when the construct is introduced 
into a biological environment due to the unique nature of a construct’s adsorption binding 
kinetics (10). 
Agricultural and food processing applications have made extensive use of 
immobilized enzymes, primarily as a means reduce total cost by easing component 
handling and extending the lifespan of the attached enzymes.  Glucose isomerase for 
conversion of raw glucose syrup to high fructose corn syrup is immobilized to a variety 
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of supports to extend the functional lifetime and ease handling of the enzyme (11). 
Immobilized L-aminoacylase is utilized to produce L-amino acids from racemic stock 
mixtures (12).  The lower activity of nonspecifically adsorbed or immobilized enzymes is 
an acceptable limitation in an industrial process (13). 
Facile multifunctional nanoparticle development has only recently become 
possible due to advances in biocompatible chemical conjugation, nanoparticle surface 
functionalization and micro scale enzyme function assays. Traditionally, elements in a 
multifunctional construct were selected for their additive value (e.g. increased longevity) 
and for their ease of conjugation.  A standardized synthetic strategy utilizing a 
nanoparticle platform moves multifunctional constructs to a paradigm where synergy 
between components, not simple additive features or ease of conjugation, is the focus of 
synthesis. 
Multifunctional nanoparticle platforms hold promise to combine the simple 
assembly and lifespan of industrial enzyme-adsorbed microparticles with the small 
dimensions and controlled synthesis of clinically relevant tagged antibodies and enzymes.  
Introduction of reactive groups (i.e. sulfhydryl and maleimide) to the ligand and particle 
support provide a single thioether binding method that is a stable, well-characterized 
synthetic route.  Introduction of the reactive groups also provides a means to control the 
absolute and relative number of ligands bound on the particle surface. 
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Methodology 
 
Sulfhydryl modification of enzymes 
 Aceylated sulfhydryl groups were introduced to the surface of horseradish 
peroxidase, α-glucosidase, and collagenase using N-succinimidyl-S-acetylthiopropionate 
(SATP, Pierce) based on the method described by Duncan et al. (5). Horseradish 
peroxidase (1.5 mg) purified from A. rusticana root (01-2001, Invitrogen), α-glucosidase 
(1.5 mg) purified from S. cerevisiae (63412, Fluka), and collagenase (1.5 mg) purified 
from C. histolyticum (CLSPA, Worthington Biochemical) were each dissolved in 1 mL of 
pH 7.5 phosphate buffered saline (PBS). SATP (0.45, 0.58, 0.92 mg, respectively, for 
horseradish peroxidase, α-glucosidase, and collagenase) was dissolved in 6 µL 
dimethylsulfoxide (DMSO) and incubated with each enzyme solutions at 25 °C for 30 
minutes at a 100:1 SATP:enzyme molar ratio. Acelyated SATP labeled protein was 
purified by four-fold centrifugal separation with 30 kDa cutoff filters (Amicon). Acetyl 
protective groups were removed by incubating the labeled protein in a solution containing 
0.5 mol L-1 hydroxylamine and 25 mmol L-1 ethylenediaminetetraacetic acid (EDTA) in 
PBS, pH 7.2 for two hours at 25 °C. Sulfhydryl-modified protein was purified from 
hydroxylamine by four-fold centrifugal separation with 30 kDa cutoff filters (Amicon).  
Protein concentration was analyzed by absorbance at 280 nm. 
 
Quantification of SH labeling efficiency 
 Enzyme-associated sulfhydryl groups were quantified by Ellman’s Method (14).  
Samples of each enzyme were prepared in 0.1 mol L-1 sodium phosphate, 1 mmol L-1 
EDTA buffer, pH 8.0.  Four milligrams of 5,5'-Dithio-bis-(2-nitrobenzoic acid)(DTNB, 
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Pierce) were dissolved per milliliter of buffer.  The DTNB solution was mixed at a 
1:50:0.1 buffer:DNTB solution:enzyme sample ratio, respectively, and reacted for 15 
minutes at 25 ºC.  Absorbance at 412 nm was measured and the concentration of colored 
reactant was quantified based on a 14150 M-1 cm-1 molar extinction coefficient. Protein 
concentration was analyzed separately by absorbance at 280 nm. Intrinsic horseradish 
peroxidase absorption at 412 nm was subtracted from values measured from Ellman’s 
Method. Intrinsic α-glucosidase and collagenase absorption at 412 nm was negligible. 
 
NP characteristics 
Superparamagnetic (SPM) NPs were obtained from micromod 
Partikeltechnologie GmbH (Germany) with 300 Da polyethylene glycol (PEG) surface 
molecules (145 nm radius). The manufacturer reported a diameter CV of 0.47.  The NPs 
had a smooth surface as observed by transmission electron microscopy.  The NP was a 
Fe3O4-dextran-silica composite of an inner continuous phase dextran containing Fe3O4 
crystals and a dextran-silica composite shell.  The PEG terminus was a primary amine 
group.  Percentage Fe3O4 mass composition was 75%. The NP volumetric magnetic 
susceptibility (χV) was 0.2105 for under saturating conditions (H > 7.96 x 105 A m-1). 
 
Heterobifunctional linker modification of SPM NP surface 
 Primary amines on surface PEG groups of the SPM NPs were modified to form 
maleimide reactive groups.  The heterobifunctional crosslinker, sulfosuccinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC, Pierce) was utilized to bind 
the sulfhydryl modified enzymes to the PEG groups on the SPM NP in a variation of the 
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method described by Duncan et al. (5).  SPM NPs (400 mg) in 0.1 mol L-1 sodium 
phosphate, 2.5 mmol L-1 EDTA buffer, pH 7.4 were mixed with 2 mg Sulfo-SMCC in an 
inverting mixer at 37 ºC for 30 minutes.  Sulfo-SMCC modified NPs were magnetically 
washed four times (1 x 106 dilution of reactant) into 0.1 mol L-1 sodium phosphate, 10 
mmol L-1 EDTA buffer, pH 7.4. 
 
Enzyme-nanoparticle conjugation 
 Sulfhydryl labeled horseradish peroxidase, α-glucosidase, and collagenase were 
mixed in an equal molar ratio solution. The equimolar enzyme solution was mixed with 2 
mg sulfo-SMCC modified NPs by inversion in 0.1 mol L-1 sodium phosphate, 10 mmol 
L-1 EDTA buffer, pH 7.4 at 4º C for 1 hour at a 10,000:1 enzyme:NP molar ratio.  
Unconjugated enzyme was removed by magnetically washing the nanoparticles four 
times (1 x 106 dilution of reactant) into 0.1 mol L-1 sodium phosphate, 10 mmol L-1 
EDTA buffer, pH 7.4. 
 
Enzymatic activity assay 
Horseradish peroxidase was assayed by measurement of the fluorescent product 
generated from 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red, Invitrogen)(15).  One 
horseradish peroxidase purpurogallin unit catalyzes the oxidation of 1 mg pyrogallol to 
purpurogallin in 20 seconds at 20 °C and pH 6.0.  α-glucosidase was assayed by 
measurement of the colorimetric p-nitrophenol product generated from 4-nitrophenyl-α-
D-glucopyranoside (PNPG) as previously described by Baroli et al. (16).  One unit of α-
glucosidase corresponds to the amount of enzyme that hydrolyzes 1 μmol p-nitrophenyl-
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α-D-glucopyranoside per minute at pH 6.8 and 37 °C (after 1- 2 hours preincubation in 20 
mM borate, pH 9.1, 4°C).  Collagenase activity was assayed by fluorescence production 
from a dye-quenched gelatin substrate (Invitrogen) at 25 ºC.  One collagenase unit 
released one micromole of L-leucine equivalents from collagen I in five hours at 37 °C, 
pH 7.5.  NP attenuation of fluorescence from the fluorogenic substrate was corrected with 
an attenuation standard of fluorogenic substrate and SPM NPs.  NP absorbance at 400 nm 
was similarly subtracted from values measured in the α-glucosidase assay system. 
Experimental values for functional enzyme molecules per NP were calculated based on a 
standard curve of enzyme concentrations of known activity and NP optical attenuation. 
 
Results 
 
Conjugation of three enzyme species to maleimide activated nanoparticle surface. 
Three enzyme species, horseradish peroxidase, α-glucosidase, and collagenase 
were successfully conjugated to the nanoparticle surface in a functional state by a 
sulfhydryl-maleimide linkage (Figure 1).  Sulfhydryl-reactive, PEG-maleimide coated 
NPs that were mixed with enzymes for covalent conjugation possessed specific function 
equivalent to 15 ± 3 horseradish peroxidase enzymes, 127 ± 21 α-glucosidase enzymes, 
and 103 ± 24 collagenase enzymes per NP.  PEG-coated NPs lacking the sulfhydryl-
reactive maleimide group and treated with the same reactive enzyme mixture had 
functional activity equivalent to 1 ± 0 horseradish peroxidase enzymes, 11 ± 1                
α-glucosidase enzymes, and 4 ± 3 collagenase enzymes per NP.   
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Minimal cross reactivity of enzymes in corresponding assay systems. 
Enzyme cross reactivity between enzyme-specific assay systems was minimal 
(Figure 2).  The enzymatic assay systems were linear over the measured range of 0 to 3 
mU mL-1, 0 to 50 mU mL-1, and 0 to 500 mU mL-1 for horseradish peroxidase, α-
glucosidase, and collagenase, respectively. 
50 mU mL-1 α-glucosidase activity in the horseradish peroxidase assay system 
was equivalent to 0.13 mU mL-1 horseradish peroxidase activity.  500 mU mL-1 
collagenase activity in the horseradish peroxidase assay system was equivalent to 0.021 
mU mL-1 horseradish peroxidase activity.   
3 mU mL-1 horseradish peroxidase activity in the α-glucosidase assay system was 
equivalent to 2.5 mU mL-1 α-glucosidase activity.  500 mU mL-1 collagenase activity in 
the α-glucosidase assay system was equivalent to 2.4 mU mL-1 α-glucosidase activity.   
50 mU mL-1 α-glucosidase activity in the collagenase assay system was 
equivalent to 0 mU mL-1 collagenase activity.  3 mU mL-1 horseradish peroxidase activity 
in the collagenase assay system was equivalent to 0 mU mL-1 collagenase activity. 
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 Figure 1.  Simultaneous conjugation of three enzyme species was successfully carried out 
on maleimide-activated nanoparticles.  Primary amine-PEG coated NPs were activated 
with sulfo-SMCC to yield a maleimide-activated NP surface.  Each enzyme species was 
treated with SATP to create surface-available sulfhydryl groups (Table 1).  Enzymes 
were mixed at 3,333:1 enzyme:NP ratio at 4 ºC for one hour (10,000:1 total molar ratio) 
with amine-PEG (unreactive control) and maleimide-PEG NPs.  Unbound enzymes were 
removed by four-fold magnetic separation of NPs from free enzymes.  Enzymes bound 
per NP were quantified by enzyme-specific fluorometric and colorimetric assays. n = 1, 
error bars = std. dev. of triplicate measurement. 
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 Figure 2.  Collagenase (C), horseradish peroxidase (H), and α-glucosidase (G) had 
minimal cross reactivity in enzyme activity assay systems.  For each assay system, the 
left three bars are the maximum, minimum and background assay values from a linear 
five-point standard curve to calibrate assay range for a single enzyme (e.g. H).  The two 
bars to the right in each assay set represent the enzyme cross reactivity produced by the 
maximum concentration of other enzymes (e.g. G and C) in the absence of the native 
enzyme (e.g. H).  Activity values were normalized to the fluorescence or absorbance 
value of the maximum enzyme concentration utilized in each assay system.  Activity 
values were derived from enzyme specific fluorometric and colorimetric assays. Enzyme 
units are mU mL-1. n = 3, error bars = std. dev. of triplicate measurement.   
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SATP modification of each enzyme species does not interfere with enzyme function. 
SATP modification of each enzyme species did not interfere with enzyme function 
(Figure 3).  Sulfhydral labeling of the enzyme species at a 100:1 SATP:enzyme molar 
ratio resulted in 5.7 ± 0.5 SH: horseradish peroxidase, 5.4 ± 1.1 SH: α-glucosidase, and 
29 ± 12 SH:collagenase molecule (Table 1).  Enzymatic activity in each case was 
undiminished compared to untreated control samples. 
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Figure 3. SATP modification of each enzyme species did not interfere with enzyme 
function.  Each enzyme species was modified with a 100:1 SATP:enzyme molar ratio.  
Enzyme function was quantified by enzyme-specific fluorometric and colorimetric assay.   
Activity values were normalized to untreated enzyme samples (i.e. native) for each 
species. n = 3, error bars = std. dev. P > 0.24 between all native-SATP pairs by paired t-
test. 
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 Horseradish 
Peroxidase α-Glucosidase Collagenase 
Native 0.55 ± 0.53  0.44  ± 0.16  0.21  ±   0.23 
SATP 5.7   ± 3.3  5.4    ± 1.1 29      ± 12 
 
Table 1.  SATP reaction significantly increased the number of reactive sulfhydral 
groups on each enzyme species.  Each enzyme species was treated with a 100:1 
SATP:enzyme molar ratio for 30 minutes at 25 ºC.  Surface available sulfhydryl 
groups were quantified by Ellman’s Method. Horseradish peroxidase Ellman’s values 
were corrected for intrinsic A412 signal. n = 3, error bars = std. dev.  P < 0.001 
between all Native / SATP pairs by Mann-Whitney Rank Sum Test. 
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Discussion 
Sulfhydryl-maleimide mediated covalent binding of three different lytic enzyme 
species to a NP surface demonstrates the flexibility of this conjugation approach to the 
formation of complex biomolecule-NP structures.  Additional functional groups can be 
added with the same sulfhydryl-maleimide reactive chemistry in a controlled fashion 
through regulation of the relative molar ratios of each component during conjugation. We 
have previously demonstrated that the NP surface has approximately 1550 reactive 
groups, indicating substantial residual binding capacity (Manuscript 2). 
Although our data show limited cross reactivity, other sets of biological ligands 
may generate levels of interassay cross reactivity.  Assessment of enzyme cross-reactivity 
is a straightforward process that can be performed during the course of purification or 
enzyme activity measurement.  Cross reactivity may be eliminated by choosing an 
alternate assessment system, or by mathematical compensation.  
SATP reaction was a benign modification of the enzymes.  For biomolecules that 
require primary amine availability for function, alternate strategies may be pursued, 
including incorporation of sulfhydryl groups during ligand synthesis, altered reaction 
conditions, or the use of other sulfhydryl-additive reactive chemicals such as cystamine 
that modify carboxylates and phosphates instead of primary amine groups. 
 The use of NPs as a binding platform has several notable features that enable the 
development of a multifunctional biological model system.  The NP surface provides a 
uniform binding environment and reaction chemistry for attaching ligands.  The small 
size of the nanoparticle mimics the size scale of protein arrangements in the cell 
membrane or in cell-cell interactions, providing an accurate spatial arrangement for 
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mimicry of biological interactions.  PEG coating on the surface of the NPs allows further 
refinement of the platform.  PEG chain length can be modulated to provide a small 
surface stand-off to a long tether, providing either rotational freedom and enhanced 
surface area, or full solution mobility, respectively. 
Multifunctional nanoparticles that mimic particular cellular behaviors such as 
proteolytic extracellular matrix invasion or immune cell-cell interactions will provide an 
ideal test structure for screening clinically relevant therapeutic compounds.  Controlled, 
thoroughly characterized, nanoparticles that provide specific and controllable 
functionality may enable enhanced pharmaceutical development through improved 
understanding of complex biological mechanisms such antigen presenting cell-T-cell 
interactions or the proteolytic behavior of metastatic cells (1, 17, 18).   
Multifunctional nanoparticles allow a bottom-up approach to studying complex 
cellular and biological phenomena.  Rather than eliminating single, or groups of surface 
ligands from cell populations, the multifunctional nanoparticles can be constructed to 
contain only a select set of surface groups.  These specifically constructed nanoparticles 
allow study of complex interactions among a specified set of ligands, allowing direct 
observation of phenomena, rather than inference of the role of each ligand in complex 
biological behaviors. 
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CHAPTER V 
 
PROTECTION OF RESEARCH SUBJECTS AND SOCIETAL IMPLICATIONS 
 
Protection of Research Subjects 
Murine subjects covered under Vanderbilt’s IACUC approved protocols 
M/99/093, M/04/352, M/04/105, and M/03/600 were utilized in these studies.  Subjects 
were given injectable or gas anesthesia as necessary to prevent or minimize pain.  Live 
animal and animal-derived tissue use was minimized in this work.  Animal-derived tissue 
was utilized in a fashion to minimize the total number of animals necessary.   
 Appropriate training on standard chemical, biological and radiation safety and 
animal handling, techniques and procedures was provided for personnel involved in this 
study in compliance with institutional guidelines.  The methods utilized in the course of 
these experiments minimized exposure to potentially infectious material for scientists 
directly involved in the research as well as other personnel. 
 
Societal Implications 
 Legal and ethical concerns of this work were minimal, as it extended prior efforts 
to direct therapeutic intervention into a substantial worldwide cause of mortality and 
morbidity.  Economic results of a successful development of a novel interstitial system of 
therapy delivery and dispersion may include production of intellectual and physical 
property of value both to the developing institution and to potential industrial partners. 
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 CHAPTER VI 
 
CONCLUSIONS 
 
Summary of Manuscripts 
 This dissertation is composed principally of three manuscripts that detail a 
comprehensive system for the design, synthesis, mathematical description, and in vitro 
testing of multifunctional superparamagnetic nanoparticles (SPM NPs).  The three 
Specific Aims detailed in Chapter I were explored as is described in three manuscripts 
(Chapters II, III, and IV), each devoted to a single Specific Aim.  These manuscripts 
describe a system of new materials and methods that will allow the clinical development 
of carriers for macromolecular and nanoscale therapeutic agents with facilitated 
interstitial mobility.  Additionally, these reports detail an experimental system that may 
find broad application in basic science study of invasive cellular behaviors. 
 In Chapter II, we developed an in vitro system to quantify the suitability of SPM 
NPs as a site-specific therapeutic vehicle for enhanced transport through fluid and gel 
based sites. NP diameter and surface coating were found to be predictive characteristics 
of SPM NP mobility in purified extracellular matrix.  The observed velocities are suitable 
for some clinical applications in macromolecular dispersion.  Aggregation played a 
critical role in determining the behavior of the NPs, consolidating the NP into a central 
aggregate during gel migration. 
Steric barriers such as collagen I fibers sharply limit mobility of macromolecular 
and NP based therapeutic agents in the interstitial space. To overcome this barrier we 
91 
 developed and demonstrated in vitro activity of a multifunctional collagenase-NP 
conjugate, detailed in Chapter III. In the course of this effort, we developed a synthetic 
strategy that provides temporal control of the level of proteolytic enzyme bound on the 
NP surface. Collagenase-linked, PEG-coated NPs moved through an alloy gel system 
composed of purified extracellular matrix and collagen I with a velocity suitable for some 
clinical applications.  The observed rate also closely approximates the migration rate of 
invasive cells and bacteria through tissue.  Temporal decay of collagenase activity shifted 
from an exponential behavior in solution to a linear relationship when NP-attached, 
producing greater total activity over the course of the collagenase lifetime.  The chemical 
addition of sulfhydryl groups to the collagenase surface did not interfere with enzymatic 
function at saturation labeling (nine sulfhydryl groups per collagenase enzyme).   
The unified strategy of utilizing introduced sulfhydryl groups to bind proteins to 
the surface of maleimide activated NPs is a simple and versatile synthetic strategy 
suitable for tethering a vast array of biomolecules to the NP surface.  While sulfhydral-
maleimide conjugation has been previously utilized to covalently link biomolecules 
together (e.g. fluorescence marker and antibody), the strategy developed in Chapter III 
and IV employed a constant NP platform, simplifying creation of conjugates that 
potentially incorporate dozens of unique functional groups. 
Multifunctional NPs mimic invasive biological processes found in metastatic 
invasion and neuronal development. In Chapter IV, we have demonstrated a facile 
method of conjugating multiple enzyme species to a NP via sulfhydryl-maleimide 
reaction chemistry. Horseradish peroxidase, α-glucosidase, and collagenase were 
conjugated to the 300 Da PEG surface of SPM NPs at 15:1, 127:1 and 103:1 functional 
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 enzyme:NP ratio, respectively.  Cross reactivity of enzymes between enzyme activity 
assay systems was negligible. 
Basic science study of invasive biological processes can utilize multifunctional 
NPs as models with specific multifunctional proteolytic capabilities.  The greatly 
enhanced mobility of surface functionalized SPM NP carriers in the interstitial space 
suggests application for clinical dispersion of large macromolecular therapeutic agents.  
In both cases, candidate NP conjugates can be developed based on mathematically and 
analytically characterized behavior derived from the in vitro experimental system 
developed in Chapters II and III that mimics the geometric and chemical properties of the 
extracellular matrix.  Applications for specific surface functionalizations can adapt 
synthesis and analysis strategies discussed in Chapters III and IV for mono and 
multivalent enzyme-NP constructs. 
 
Long Term Future Studies 
 
Clinical dispersion of otherwise immobile therapeutics 
 Advanced therapeutic agents including large proteins, NPs, liposomes and gene 
therapy vectors are limited in their clinical application, in part, by poor interstitial 
mobility. These nanoscale therapeutic agents will allow development of treatment 
strategies for disease states such as genetic disorders that are poorly treated by 
conventional molecular therapeutic agents.  Dispersion of otherwise immobile 
macromolecular or nanoscale therapeutic structures can presumably be achieved with the 
proteolytic SPM NP carriers detailed in this work. Enhanced dispersion may also be a 
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 tool to reduce the total number of injection sites utilized to delivery minimally mobile 
structures such as radiotherapy microdosimetry capsules.  
 
Study of proteolytic cell movement 
 Basic research into the mechanics of invasive cellular processes has historically 
relied on genetic modification of organisms and / or the introduction of chemical control 
agents to the experimental system.  Use of genetic modifications or chemical agents 
retains much of the system complexity that limits interpretation or isolation of particular 
behaviors. The experimental techniques described in chapters II, III, and IV allow direct 
study of the contribution of a single protein or a set of surface-bound proteins during 
invasive cell or cell-group behavior.   
In addition to a greater mechanical understanding of cellular behavior, isolated 
study of sets of enzymes in an invasion experimental system may make an ideal 
screening tool for blocking pathogenic invasive processes.  Invasive cellular processes 
play a significant role in a variety of pathological processes, including cancer metastasis 
and necrotizing fasciitis. The ability to control the critical aspects of the model system, 
including the type and activity of proteolytic enzyme activity, the composition of the 
barrier material and the magnetic driving force for motion, offers a unique and powerful 
platform for sophisticated mechanistic study of cell and bacterial invasion. 
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 Short Term Experimental Aims 
 
Optimization of enzyme selection for interstitial invasion 
As detailed in Chapter III, collagen I is significant physical barrier to interstitial 
transport of nanoscale structures.  However, other significant barriers exist, including 
glycoproteins and other structural proteins.  An in-depth literature survey may suggest 
other interstitial degradation targets.  The enzymes that degrade these targets may then be 
incorporated into the existing enzyme-NP construct by using existing methodology 
detailed in Chapter IV, and tested in alloy gels that contain the target substances in a 
variation of the methods in Chapter III. 
 
Test enzyme-NP conjugates in vivo 
 Although difficulties were encountered during the ex vivo efforts (Appendix A), 
in vivo studies may prove to be a more fruitful method of testing the efficacy of the 
proteolytic NPs for interstitial dispersion.   Due to current IACUC regulations that restrict 
applications of funds to in vivo work, this effort would be best carried out as part of a 
specific funding proposal at the institutional, or national level.   
 As evidenced in Appendix B, planar x-ray imaging of the NPs may prove to be a 
sufficient method for whole-animal detection of mobility.  Histological examination can 
provide the tissue-level documentation of NP mobility in mice.  Perls’ Method Prussian 
Blue stain will detect the presence of iron in tissue samples.  Whole tissue enzyme 
blotting or activity-specific staining systems can provide information about the 
localization of the enzyme activity (1). 
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 Mathematical modeling of current work 
 A mathematical model system to estimate the role of proteolytic enzymes during 
invasive cell behavior may be constructed based on the mathematical estimation of NP 
mobility and in vitro system in Chapter II and the synthetic and in vitro testing methods 
in Chapter III.  Integrated with the multifunctional NPs described in Chapter IV, the 
mathematical model would elucidate the interplay between mobility and proteolytic 
enzymes on the cellular level. 
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Introduction 
Translation of previous in vitro testing of nanoparticle conjugates into clinical 
methods may be accomplished in an ex vivo tumor tissue system.  Tissue offers 
sophistication in structure and composition that is not present in purified extracellular 
matrix.  The in vitro substrate utilized in previous studies (Manuscripts I, II) did not have 
structural elements larger than the macromolecular level such as cells, vessels or tissue 
planes.  The purification process for preparation of the extracellular matrix gel likely 
removes many functional proteins typically found in the interstitium, including enzyme 
inhibitors such as tissue inhibitors of metalloproteases (TIMPs). The structural and 
functional elements not present in the in vitro system may play a significant role during 
in vivo applications. 
Three separate avenues for ex vivo tissue work were proposed: an excised whole 
tumor retained in a plastic frame and visualized with planar x-ray (Figure 1), a modified 
well migration assay utilizing discs of tumor tissue (Figure 2), and a layered purified 
extracellular matrix-tumor-extracellular matrix system (Figure 3). Excised whole tumor 
had the advantage of being the most accurate ex vivo model of expected in vivo 
application.  Thin tumor sections in a transmigration assay leveraged existing migration 
assay technology.  Layered tumor homogenate systems were a simple extension of the 
mature in vitro system. 
 While nanoparticles were clearly visible in all systems, by either white-light 
illumination or x-ray imaging, the tissue substrates proved unstable during the 3 – 24 
hour time course required for ex vivo studies.  The whole tumor system deformed at a rate  
that would have obscured the expected minute mobility of the nanoparticles in the tissue.  
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The thin tumor section transmigration assay was compromised by an inability to design a 
system that would prevent and discrimination nanoparticle migration around, rather than 
through, the tissue section.  Nanoparticles introduced to the tumor homogenate layer 
system had two discrete behavior patterns: trapping in the homogenate layer or 
circumvention of the homogenate layer. 
There were several weaknesses that prevented successful development and 
application of an ex vivo system.  Procedural concerns regarding the stability of ex vivo 
tissue samples, limited ability to control the path of nanoparticles through tissue, and 
administrative limitations regarding tissue and instrument availability were primary 
barriers to successful implementation of an ex vivo experimental system. 
Preliminary experiments were completed, including whole tissue stability time course 
studies, planar x-ray imaging feasibility, and hybrid matrix-tumor-matrix penetration 
experiments with native nanoparticles.  All systems had substantial difficulties that 
compromised their application and development. 
 
Barriers to Ex Vivo System Development 
 
Tissue was unstable over the experimental time course 
The tissue underwent macroscopic deformation within three hours (Figure 4) and 
continued to degrade at longer time intervals.  This deformation was much larger than the 
magnitude of motion we would have expected to observe from nanoparticle conjugate 
motion in the tissue, thus preventing useful analysis of the data. 
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Lengthy assay system development 
  Development of a new assay system may have required construction, 
troubleshooting, and quality control work unrelated to testing the nanoparticles.  Once an 
assay system was successfully developed, the experimental phase may have generated no 
useful data.  The assay system itself was unlikely to be publishable in the absence of data 
demonstrating nanoparticle motion.  In both cases, assay development required freshly 
harvested animal tissue rather than store-bought tissue due to the rapid degradation of 
tissue following sacrifice. 
 
Animal tissue procurement 
a. IACUC regulations allowed use of harvested tissue from animals utilized 
under existing IACUC protocols for other, “off protocol” applications.  
However, that mechanism only would have provided for sporadic 
availability of small numbers of tissue samples.  The coordination of 
animal tissue availability, vibratome access, and fresh synthesis of the 
nanoparticles would have made development of a useful sample size of 
tissue an exceptionally challenging. 
b. Dr. Chris Kao (Neurological Surgery) volunteered use of his vibratome to 
section live tissue into one millimeter discs.  Use of the vibratome with 
arbitrary tissue samples (e.g. tissue from a grocery store) to develop the 
assay system was prohibited.  Dr. Kao had strict rules about sample 
contamination and cleanliness that prohibited use of anything but freshly 
harvested tissue on the vibratome.  Dr. Anita Mahadevan-Jansen devoted 
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her thick tissue slicer exclusively to human tissue samples. The inability to 
utilize mock tissue for assay development further impeded the 
development course of the ex vivo assay system. 
 
In the well-plate based assay limiting nanoparticle migration through, rather than around, 
the sample was a challenging design element.  
 
Even a small capacity for nanoparticle transport that ‘short-circuits’ around the 
tissue sample was hypothesized to significantly complicate quantitation of nanoparticle 
transport through the tissue.  Substances that would have bonded the tissue to the surface 
of the support or edges of the well may have diffused into the tissue itself, thus 
compromising the tissue structure.  Bonding the tissue to the dish may also have made 
post-experimental histological analysis difficult. 
 
SPM NPs were unable to penetrate layered ECM-tumor homogenate-ECM except by 
circumventing the tumor homogenate layer.  
 
A layered system of  50 uL purified ECM, Lewis Lung Carcinoma (LLC) 
homogenate, 40 uL purified ECM in glass microvials was developed to examine the 
mobility of the SPM NPs in vitro (Figure 3).  This system built upon previous success of 
examining SPM NP mobility in purified ECM alone under similar experimental 
conditions. LLC tumor homogenate was procured from LLC tumors in murine subjects 
and homogenized to a paste.  The vials were assembled as previously described 
(Manuscript 1) with the addition of an intermediary layer of LLC homogenate.  The LLC 
homogenate layer was designed to provide additional resistance and interaction 
opportunities with biological material for the SPM NPs over the purified ECM alone.   
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The SPM NPs were unable to penetrate the homogenized LLC tissue.  At low 
concentrations, the NPs entered the distal face of the ECM layer relative to the magnet 
and penetrated less than 1 mm overnight.  At higher concentrations, NPs migrated around 
the layer of LLC homogenate along the walls of the glass microvials.  Initial assembly 
difficulties with trapped air in the tumor homogenate were resolved by serial additions of 
tumor homogenate, followed by a degassing period of 4 ºC for several hours, followed by 
addition of tumor homogenate, as needed to reach several millimeters of tumor 
homogenate depth in the glass vial. 
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 Figure 1. Whole tumor ex vivo nanoparticle mobility assay design. Upper image illustrates 
a flattened schematic of the frame. Notations indicate cutouts in the polycarbonate plastic 
frame to allow unattenuated planar x-ray imaging.  Injection port was available for needle 
access to tissue.  
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Figure 2. Tumor disc, well plate based nanoparticle mobility assay.  Nanoparticle 
penetration through the tissue was proposed to be assayed by visible absorbance (UV/ 
Vis spec) and by histology of the tissue disc. 
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Figure 3. Layered in vitro model system of Lewis Lung Carcinoma (LLC) tumor 
homogenate and purified ECM gel was unsuitable for studying the penetration of tumor 
tissue by SPM NPs due to NP mobility along the surface of the container.  300Da PEG 
surface coated SPM NPs were introduced to the surface of the layered construct at 
various concentrations from 0.2 mg mL-1 to 10 mg mL-1.  At concentrations above 5 mg 
mL-1 NPs migrated to the bottom of the vial by movement along the glass surface of the 
vial within 30 minutes.  At concentrations below 5 mg mL-1, NPs penetrated into the 
tumor homogenate approximately 500 μm before becoming immobilized.  
A 10 mg mL-1,   t =     5 minutes 
B 10 mg mL-1,   t =     5 minutes  
C  5 mg mL-1,    t =   30 minutes 
D  1 mg mL-1,    t =  720 minutes 
E  0.2 mg mL-1,  t = 720 minutes 
F  0.2 mg mL-1,  t = 720 minutes 
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Figure 4.  Fresh tissue exhibited substantial deformation over the course of 9 hours.  
Tissue deformation is presented as regions of colored material.  Tissue deformation 
utilized the whole tissue imaging system (Figure 1).  Fresh chicken liver tissue was 
coated in iron filings and placed in the ~ 1 cm3 plastic frame.  Liquid agarose was 
utilized to provide support and displace air in the frame.  Tissue samples were first 
washed three-fold and held in isotonic saline with 5mM azide and standard cell culture 
antibiotic cocktail for nine hours at 37 ºC.  Three samples were imaged by planar x-ray at 
t=0, 4 and 9 hours (cyan, magenta, yellow respectively).  The three images were colored 
and digitally merged. Iron filings are high contrast regions in x-ray imaging and appear 
colored or black in this image set. Immobile iron filings appear black.  Mobile iron filings 
appear as colored regions. 
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Hypothesis 
 
We hypothesized that a magnetic force applied to a SPM NP by an external permanent 
magnet may be used to overcome barriers that limit the transport and uniform distribution 
of intratumorally delivered antitumor therapies. 
 
Methodology 
 
NP Characteristics 
SPM NPs were obtained from micromod Partikeltechnologie GmbH (Rostock-
Warnemuende, Germany). The NPs had a narrow size distribution and a smooth surface 
as observed by transmission electron microscopy. The NP is a Fe3O4-dextran-silica 
composite NP that consists of an inner region of continuous phase dextran containing 
Fe3O4 crystals, with an outer shell of a dextran-silica composite.  Total Fe3O4 composition 
by mass is 75%.  Two NP cohorts were utilized: one cohort was not functionalized, 
providing the native characteristics of the dextran-silica shell on the NP surface (270 nm 
diameter), the other cohort was surface functionalized with 300 Da polyethylene glycol 
(290 nm diameter). 
 
Lewis Lung Carcinoma Growth in Murine Subjects 
Adult, male, 57/BL6 mice obtained from Jackson Labs were utilized as subjects.  
Both hind limbs  of each animal were seeded with 8 x 105 Lewis Lung Carcinoma cells 
109 
(LLC1) (ATCC, USA) (1).  Tumors were grown over the course of 12 days to a size of 
1.5 cm diameter. 
 
Introduction of SPM NPs into Murine Subjects 
50 μL of 10 mg mL-1 suspension of NPs were injected from the dorsal surface at 
the distal end of the tumor into the core region of the tumor.  The injection volume was 
introduced under low pressure.  Any leakage of fluid from the injection subsequent to 
needle withdrawal was absorbed and removed from the field of view.  A one tesla surface 
strength permanent NdFeB magnet (Edmund Scientific) was placed against the proximal 
end of the tumor immediately following the initial injection, and maintained throughout 
the course of the experiment.   
 
X-ray Imaging of SPM NPs in Murine Subjects  
250 μL of a ketamine solution (200 mg kg-1) was subcutaneously injected in the 
abdomen of each mouse to restrict movement of the subject over the course of imaging.  
X-ray imaging of the murine subjects was carried out using a GE Senographe 600T 
mammography unit.  The subjects were restrained on the upper surface of the sample 
platform using laboratory tape to prevent movement of the limbs during imaging.  X-ray 
images were obtained using 26 kV and 5 mAs exposure.  Kodak MIN-R 2000 film (CAT 
812 6393) was utilized in a Kodak MIN-R cassette, 4 cm below the imaging platform.  
The imaging system was certified to produce a maximum resolution of 16 line pairs per 
mm.  Images were obtained to document the condition of the tumor prior to treatment, 
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immediately after injection of SPM NPs, and at several time points following the 
injection during application of a 1.0 T magnetic field. 
 
NP Coating Impact on Agglomeration Behavior 
The solution agglomeration behavior of two cohorts of NPs was measured by 
light scatter in an aggregometer (Chrono-log corp.).  A 5.8 mT permanent magnet (1.2 
mT at maximum fluid height) was present on the bottom surface of the 2 mL vials used 
for analysis.  270 nm silica-dextran NPs (micromod, 13-00-252) and 290 nm NH2-PEG 
silica-dextran NPs (micromod, 13-55-252) were compared in a variety of solvents at 0.25 
mg mL-1 concentration (Figure 3). 
 
Results 
 
Silica Dextran NP Interstitial Mobility 
Motion of silica-dextran and PEG coated micromod NPs injected into LLC 
tumors was undetectable from their injection site over the course of 60 minute exposure 
to a 1.0 T magnetic field (Figure 1Figure 2).  The minimum distance observable using X-
ray imaging is 7.69 x 10-4 m.  The lack of detection of NP motion indicates that the upper 
limit of NP velocity over the 60 minute experimental course is 2.14 x 10-7 ms-1. 
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Control Experimental 
  
  
  
Figure 1. Time based series of micromod SPM NP injection into LLC tumor in murine 
hind limb.  In both limbs, the SPM NPs are visible as a region of high contrast in the 
interior angle between the upper and lower hind limb.   A. Control limb, prior to 
injection.  B. Control limb, 5 minutes post injection. C. Control limb, 60 minutes post 
injection.  D. Experimental limb, prior to injection.  E. Experimental limb, 5 minutes 
post injection. Region of solid contrast (white) illustrates permanent magnet placement. 
F. Experimental limb, 60 minutes post injection.   
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Figure 2.  PEG coated nanomag (290 nm diameter) nanoparticle mobility over 60 
minutes in LLC tumors in mice was negligable.  SPM NPs are visible as regions of 
high contrast (white).  Application of a 1.0 T surface strength magnet to the 
proximal surface of the hindlimb on one leg (left panels).  Control limb (right 
panels) leg was not exposed to magnetic field.  Images at 60-minute time point were 
computationally gamma and contrast enhanced to enable visualization of 
nanoparticle contrast. 
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PEG NP Coating Reduced Agglomeration 
In common biological solutions (i.e. normal saline, PBS, Dulbecco’s Modified 
Essential Medium + 10% fetal calf serum), the PEG coated particles had significantly 
reduced agglomeration potential versus the uncoated, silica-dextran surface NPs. 
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Figure 3. PEG surface coating substantially reduces the agglomeration behavior of SPM 
NPs in several common biological solutions.  Agglomeration fraction was resolved by 
light scatter measurement of samples.  Solvents utilized include: 0.9% saline (i.e. normal) 
(red shades), Phosphate Buffer Saline (green shades), and Dulbecco’s Modified Essential 
Medium (DMEM) with 10% Calf Serum (blue shades).  NPs with a silica-dextran 
composite surface (i.e. uncoated)(light shades: red, green, blue, yellow) were compared 
with NPs with a PEG-functionalized surface (dark shades: red, green, blue, black). n = 1. 
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Discussion 
 NP-NP aggregation or adhesion to biological structures is a well characterized 
limitation to biological applications of NPs (2, 3).  The PEG coated NPs were selected to 
minimize nonspecific binding interactions (4).  Free solution aggregation tests supported 
our hypothesis that PEG surface coating would reduce aggregation of the NPs in a 
biological environment. 
Interstitial magnetic mobility of both NP cohorts was negligible.  The lack of 
mobility of either cohort is suggestive that overcoming NP aggregation is not sufficient to 
enable interstitial NP motion.  Geometric barriers, such as interstitial collagen I fibers, 
may be the primary barrier to NP mobility in the interstitial space (5, 6). 
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